<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma - Skoetz, N - 2017 | Cochrane Library</title> <meta content="Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma - Skoetz, N - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007941.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma - Skoetz, N - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007941.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007941.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma" name="citation_title"/> <meta content="Nicole Skoetz" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="nicole.skoetz@uk-koeln.de" name="citation_author_email"/> <meta content="Andrea Will" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Ina Monsef" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Corinne Brillant" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Andreas Engert" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Bastian von Tresckow" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD007941.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/05/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007941.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007941.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007941.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antineoplastic Combined Chemotherapy Protocols [administration &amp; dosage, adverse effects, *therapeutic use]; Bleomycin [administration &amp; dosage, adverse effects]; Cyclophosphamide [administration &amp; dosage, adverse effects]; Dacarbazine [administration &amp; dosage, adverse effects]; Disease Progression; Doxorubicin [administration &amp; dosage, adverse effects]; Etoposide [administration &amp; dosage, adverse effects]; Hodgkin Disease [*drug therapy, mortality, pathology]; Prednisone [administration &amp; dosage, adverse effects]; Procarbazine [administration &amp; dosage, adverse effects]; Randomized Controlled Trials as Topic; Vinblastine [administration &amp; dosage, adverse effects]; Vincristine [administration &amp; dosage, adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007941.pub3&amp;doi=10.1002/14651858.CD007941.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="jiwTpTuf";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007941\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007941\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007941\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007941\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","de","ko","ja","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007941.pub3",title:"Comparison of first\\u2010line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma",firstPublishedDate:"May 25, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematological Malignancies Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007941.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007941.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007941.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007941.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007941.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007941.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007941.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007941.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007941.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007941.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4092 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007941.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/full#CD007941-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/full#CD007941-sec-0086"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/full#CD007941-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/full#CD007941-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/full#CD007941-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/full#CD007941-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/full#CD007941-sec-0065"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/full#CD007941-sec-0080"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/appendices#CD007941-sec-0091"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/table_n/CD007941StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/table_n/CD007941StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Comparison of first‐line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/information#CD007941-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Nicole Skoetz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/information#CD007941-cr-0003">Andrea Will</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/information#CD007941-cr-0004">Ina Monsef</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/information#CD007941-cr-0005">Corinne Brillant</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/information#CD007941-cr-0006">Andreas Engert</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007941.pub3/information#CD007941-cr-0007">Bastian von Tresckow</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/information/en#CD007941-sec-0101">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 May 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007941.pub3">https://doi.org/10.1002/14651858.CD007941.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007941-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007941-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007941-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007941-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007941-abs-0003">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007941-abs-0002">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007941-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007941-abs-0001" lang="en"> <section id="CD007941-sec-0001"> <h3 class="title" id="CD007941-sec-0001">Background</h3> <p>There are two different international standards for the treatment of early unfavourable and advanced stage Hodgkin lymphoma (HL): chemotherapy with escalated BEACOPP (bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/prednisone) regimen and chemotherapy with ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) regimen. </p> </section> <section id="CD007941-sec-0002"> <h3 class="title" id="CD007941-sec-0002">Objectives</h3> <p>To determine the advantages and disadvantages of chemotherapy including escalated BEACOPP compared to chemotherapy including ABVD in the treatment of early unfavourable or advanced stage HL as first‐line treatment. </p> </section> <section id="CD007941-sec-0003"> <h3 class="title" id="CD007941-sec-0003">Search methods</h3> <p>We searched for randomised controlled trials in MEDLINE, CENTRAL and conference proceedings (January 1985 to July 2013 and for the update to March 2017) and Embase (1985 to November 2008). Moreover we searched trial registries (March 2017; www.controlled‐trials.com, www.clinicaltrialsregister.eu/ctr‐search/search, clinicaltrials.gov, www.eortc.be, www.ghsg.org, www.ctc.usyd.edu.au, www.trialscentral.org/index.html) </p> </section> <section id="CD007941-sec-0004"> <h3 class="title" id="CD007941-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials examining chemotherapy including at least two cycles of escalated BEACOPP regimens compared with chemotherapy including at least four cycles of ABVD regimens as first‐line treatment for patients with early unfavourable stage or advanced stage HL. </p> </section> <section id="CD007941-sec-0005"> <h3 class="title" id="CD007941-sec-0005">Data collection and analysis</h3> <p>The effect measures we used were hazard ratios (HRs) for overall survival (OS), progression‐free survival (PFS) and freedom from first progression. </p> <p>We used risk ratios (RRs) relative risks to analyse harms: treatment‐related mortality, secondary malignancies (including myeloid dysplastic syndrome (MDS) or acute myeloid leukaemia (AML)), infertility and adverse events. </p> <p>Quality of life was not reported in any trial, therefore not analysed. Two review authors independently extracted data and assessed quality of trials. </p> </section> <section id="CD007941-sec-0006"> <h3 class="title" id="CD007941-sec-0006">Main results</h3> <p>We screened 1796 records and identified five eligible trials in total i.e. one trial could be added on the previous review. These trials included only adults (16 to 65 years of age). We included all five trials with 3427 people in the meta‐analyses: the HD9 and HD14 trials were co‐ordinated in Germany, the HD2000 and GSM‐HD trials were performed in Italy and the EORTC 20012 was conducted in Belgium. The overall risk of performance and detection bias was low for overall survival (OS), but was high for other outcomes, as therapy blinding was not feasible. The remaining 'Risk of bias' domains were low and unclear. </p> <p>All trials reported results for OS and progression‐free survival (PFS). In contrast to the our first published review (2011) the addition of results from the EORTC 20012 BEACOPP escalated increases OS (3142 participants; HR 0.74 (95% confidence interval (CI) 0.57 to 0.97; <i>high‐quality evidence</i> ). This means that only 90 (70 to 117) patients will die after five years in the BEACOPP escalated arm compared to 120 in the ABVD arm. This survival advantage is also reflected in an increased PFS with BEACOPP escalated (3142 participants; HR 0.54 (95% CI 0.45 to 0.64); <i>moderate‐quality evidence</i>), meaning that after five years only 144 (121 to 168) patients will experience a progress, relapse or death in the BEACOPP escalated arm compared to 250 in the ABVD arm. </p> <p>There is no evidence for a difference for treatment‐related mortality (2700 participants, RR 2.15 (95% CI = 0.93 to 4.95), <i>low‐quality evidence</i>). </p> <p>Although the occurrence of MDS or AML may increase with BEACOPP escalated (3332 participants, RR 3.90 (95% CI 1.36 to 11.21); <i>low‐quality evidence</i> )), there is no evidence for a difference between both regimens for overall secondary malignancies (3332 participants, RR 1.00 (95% CI 0.68 to 1.48), <i>low‐quality evidence</i>). However, the observation time of the studies included in the review is too short to be expected to demonstrate differences with respect to second solid tumours which would not be expected to show significance until around 15 years after treatment. </p> <p>We are very uncertain how many female patients will be infertile due to chemotherapy and which arm might be favoured (106 participants, RR 1.37 (95% CI 0.83 to 2.26), <i>very low‐quality evidence</i>). This is a very small sample, and the age of the patients was not detailed. No analysis of male fertility was provided. </p> <p>Five trials reported adverse events and the analysis shows that the escalated BEACOPP regimens probably causes more haematological toxicities WHO grade III or IV ((anaemia: 2425 participants, RR 10.67 (95% CI 7.14 to 15.93); neutropenia: 519 participants, RR 1.80 (95% CI 1.52 to 2.13); thrombocytopenia: 2425 participants, RR 18.12 (95% CI 11.77 to 27.92); infections: 2425 participants, RR 3.73 (95% CI 2.58 to 5.38), all low<i>‐quality evidence</i>). </p> <p>Only one trial (EORTC 20012) planned to assess quality of life, however, no results were reported. </p> </section> <section id="CD007941-sec-0007"> <h3 class="title" id="CD007941-sec-0007">Authors' conclusions</h3> <p>This meta‐analysis provides moderate‐ to <i>high‐quality evidence</i> that adult patients between 16 and 60 years of age with early unfavourable and advanced stage HL benefit regarding OS and PFS from first‐line chemotherapy including escalated BEACOPP. The proven benefit in OS for patients with advanced HL is a new finding of this updated review due to the inclusion of the results from the EORTC 20012 trial. Furthermore, there is only <i>low‐quality evidence</i> of a difference in the total number of secondary malignancies, as the follow‐up period might be too short to detect meaningful differences. <i>Low‐quality evidence</i> also suggests that people treated with escalated BEACOPP may have a higher risk to develop secondary AML or MDS. Due to the availability of only v<i>ery low‐quality evidence</i> available, we are unable to come to a conclusion in terms of infertility. This review does for the first time suggest a survival benefit. However, it is clear from this review that BEACOPP escalated may be more toxic that ABVD, and very important long‐term side effects of second malignancies and infertility have not been sufficiently analysed yet. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007941-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007941-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007941-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007941-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007941-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007941-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007941-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007941-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007941-abs-0005" lang="en"> <h3>Comparison of the two international standards of chemotherapy for people with early unfavourable or advanced stage Hodgkin lymphoma </h3> <p><b>Review question</b> </p> <p>For the treatment of early unfavourable and advanced stage Hodgkin lymphoma (HL) two different international standards are commonly used, either chemotherapy with escalated (intensified) BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) regimen or chemotherapy with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen. </p> <p><b>Background</b> </p> <p>Hodgkin lymphoma is a malignancy of the lymphatic system. It is one of the most common cancers in young adults, particularly in their third decade of life, but it occurs also in children and elderly people. Within the last 50 years it has become one of the most curable forms of cancer. To find the best treatment with the greatest efficacy and least toxicity is the most important challenge in treating HL. There are two international standards for the treatment of early unfavourable or advanced stage HL: chemotherapy with escalated BEACOPP regimen initiated by the German Hodgkin Study Group (GHSG) and chemotherapy with ABVD regimen, which is widely used because it has been proven to be effective, well‐tolerated and easy to administer. We aimed to clarify the advantages and disadvantages of both treatments by comparing the chance of survival (overall survival), the chance of recurrence of the tumour and the frequencies of adverse events after treatment in patients with early unfavourable stage or advanced stage HL. </p> <p><b>Study characteristics</b> </p> <p>We found five eligible trials by the date of this updated review (search date March 2017). These trials included 3427 patients adult patients (16 to 65 years of age). </p> <p><b>Key results</b> </p> <p>For this updated review there are new data available resulting in a benefit in terms of overall survival (OS) for people with early unfavourable and advanced HL receiving BEACOPP escalated for first‐line treatment. Furthermore, the analysis shows a better chance of avoiding recurrence of the tumour in patients who received chemotherapy including BEACOPP escalated. </p> <p>We analysed the following harms potentially caused by both regimens. There is no evidence for a difference for treatment‐related mortality. </p> <p>There is evidence for a higher risk of secondary acute myeloid leukaemia (AML) or myelodysplastic syndromes (MDS) in patients receiving BEACOPP escalated, but the total number of secondary malignancies does not show evidence for a difference between both treatment groups. However, the observation time of the studies included in the review is too short to be expected to demonstrate differences with respect to second solid tumours. We are very uncertain how many female patients will be infertile due to chemotherapy and which arm might be favoured, as the evaluated sample is very small. No data for male patients and risk for infertility was provided. Treatment with BEACOPP escalated caused a higher risk of adverse events such as anaemia, neutropenia, thrombocytopenia and infections. </p> <p>Quality of life was not reported by any of the included trials. One trial stated it would assess quality of life, however, there were no results reported. </p> <p><b>Quality of evidence</b> </p> <p>We assessed the quality of the evidence as high relating to overall survival, as moderate for progression‐free survival and as low for secondary AML or MDS, secondary malignancies and treatment‐related mortality and adverse events. The quality of evidence is very low for infertility. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007941-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007941-sec-0086"></div> <h3 class="title" id="CD007941-sec-0087">Implications for practice</h3> <section id="CD007941-sec-0087"> <p>The results of this meta‐analysis are based on five trials with more than 3000 patients with Hodgkin lymphoma (HL) aged between 16 and 65 years. It provides high‐quality evidence of an improved OS and moderate quality of evidence for an improved PFS for adults with unfavourable or advanced stage HL receiving first‐line treatment with escalated BEACOPP compared to ABVD. In people receiving escalated BEACOPP, more acute adverse events occur, but low‐quality evidence suggests that this does not lead to a statistical difference in treatment‐related mortality. Furthermore, there is only low‐quality evidence of a difference in the total number of secondary malignancies, as the follow‐up period might be too short to detect meaningful differences. Low‐quality evidence also suggests that people treated with escalated BEACOPP may have a higher risk of developing secondary AML or MDS. Due to the availability of only very low‐quality evidence available, we are unable to come to a conclusion in terms of infertility. This review does for the first time suggest a survival benefit. However, it is clear from this review that BEACOPPesc may be more toxic that ABVD, and very important long‐term side effects of second malignancies and infertility have not been sufficiently analysed yet. </p> </section> <h3 class="title" id="CD007941-sec-0088">Implications for research</h3> <section id="CD007941-sec-0088"> <p>Information regarding quality of live as well as long‐term toxicity (e.g. infertility, secondary malignancies, cardiac toxicity), should be of major concern for further research since most patients are diagnosed in the second or third decade of life and HL has become a curable disease for the majority of affected patients. </p> <p>Modifications of the BEACOPP escalated regimen including newer drugs and possibly less side effects are being tested by the German Hodgkyin Lymphoma Study Group to overcome adverse events, results are expected soon. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007941-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007941-sec-0036"></div> <div class="table" id="CD007941-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Escalated BEACOPP versus chemotherapy including ABVD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Patients with early unfavourable or advanced stage HL<br/> <b>Setting:</b> Hospitals<br/> <b>Intervention:</b> BEACOPP<br/> <b>Comparison:</b> ABVD </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ABVD</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with BEACOPP</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality<br/> follow up: median 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.74<br/> (0.57 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3142<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>To provide correct results by using the GRADE software, we calculated mortality instead of overall survival </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000<br/> (70 to 117) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression, relapse or death<br/> follow up: median 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.54<br/> (0.45 to 0.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3142<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>To provide correct results by using the GRADE software, we calculated progression, relapse or death instead of progression‐free survival </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000<br/> (121 to 168) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse event: treatment‐related mortality</p> <p>follow up median 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.15<br/> (0.93 to 4.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2700<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (5 to 25) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse event: secondary malignancies</p> <p>follow up median 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.00<br/> (0.68 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3332<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5, 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/> (20 to 42) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse event: secondary malignancies: AML or MDS</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.90<br/> (1.36 to 11.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3332<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (3 to 29) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse event: infertility (secondary amenorrhoea)</p> <p>follow up median 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.37<br/> (0.83 to 2.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>106<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>4, 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In the text referred to as infertility.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>375 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>514 per 1000<br/> (311 to 847) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> we estimated the risk of mortality after 5 years in the ABVD arm as being 12% </p> <p><sup>2</sup> we estimated the risk of progress, relapse or mortality after 5 years in the ABVD arm as being 25% </p> <p><sup>3</sup> one level down due to the open‐label design of the included trials which could lead to performance or detection biases </p> <p><sup>4</sup> two levels down due to very few events and wide confidence intervals (imprecision) </p> <p><sup>5</sup> one level down due to few events and wide confidence intervals (imprecision) </p> <p><sup>6</sup> one level down due to indirect results (follow‐up period not long enough to detect meaningful differences) </p> <p><sup>7</sup> one level down due to indirect results (secondary amenorrhoea measured instead of infertility) (indirectness) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007941-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007941-sec-0037"></div> <section id="CD007941-sec-0038"> <h3 class="title" id="CD007941-sec-0038">Description of the condition</h3> <p>With an annual incidence of approximately two to three per 100,000 in Western countries, Hodgkin lymphoma (HL) is a comparatively rare disease (<a href="./references#CD007941-bbs2-0076" title="National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Stat Fact Sheets: Hodgkin Lymphoma. http://seer.cancer.gov/statfacts/html/hodg.html2012. ">SEER 2012</a>). However, it is one of the most common malignancies in young adults. In industrialised countries the age distribution of HL shows a first peak in the third decade and a second peak after the age of 55 (<a href="./references#CD007941-bbs2-0079" title="SwerdlowAJ . Epidemiology of Hodgkin's disease and non‐Hodgkin's lymphoma. European Journal of Nuclear Medicine and Molecular Imaging2003;30 Suppl 1(1619‐7070 (Print)):S3‐12. ">Swerdlow 2003</a>; <a href="./references#CD007941-bbs2-0080" title="ThomasRK , ReD , ZanderT , WolfJ , DiehlV . Epidemiology and etiology of Hodgkin's lymphoma. Annals of Oncology2002;13 Suppl 4(0923‐7534 (Print)):147‐52. ">Thomas 2002</a>). </p> <p>Staging of HL is based on the Ann Arbor system (<a href="./references#CD007941-bbs2-0046" title="CarbonePP , KaplanHS , MusshoffK , SmithersDW , TubianaM . Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Research1971;31(0008‐5472):1860‐1. ">Carbone 1971</a>), B symptoms and risk factors. Risk factors for HL are, for example, large mediastinal mass, three or more involved lymph node areas, high erythrocyte sedimentation rate (ESR), extranodal lesion, advanced age; and these may vary slightly between different study groups. Additionally, the definition of bulky disease (largest tumour diameter &gt; 10 cm), often referred to as the Cotswold modification (<a href="./references#CD007941-bbs2-0070" title="ListerTA , CrowtherD , SutcliffeSB , GlatsteinE , CanellosGP , YoungRC , et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. Journal of Clinical Oncology1989;7(0732‐183X (Print), 11):1630‐6. ">Lister 1989</a>), is taken into consideration. Generally, HL is classified into early favourable, early unfavourable and advanced stage (<a href="./references#CD007941-bbs2-0058" title="EngertA , FranklinJ , EichHT , BrillantC , SehlenS , CartoniC , et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended‐field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. Journal of Clinical Oncology2007;25(1527‐7755):3495‐502. ">Engert 2007a</a>; <a href="./references#CD007941-bbs2-0068" title="KlimmB , EngertA , DiehlV . First‐line treatment of Hodgkin's lymphoma. Current Hematologic Malignancy Reports2006;1(1):51‐9. ">Klimm 2006</a>). In Europe, the early favourable stage group usually comprises Ann Arbor stages I and II without risk factors. Early unfavourable stage includes those patients in stages I and IIA with risk factors, as well as selected patients with stage IIB disease. Most stage III and IV patients are classified in the advanced stage risk group (<a href="./references#CD007941-bbs2-0052" title="DiehlV , MauchP , HarrisNL . Hodgkin's disease. Cancer: Principles and Practice of Oncology. Lippincott Williams &amp; Wilkins, 2001:2339‐87. ">Diehl 2001</a>; <a href="./references#CD007941-bbs2-0057" title="EngertA , SchillerP , JostingA , HerrmannR , KochP , SieberM , et al. Involved‐field radiotherapy is equally effective and less toxic compared with extended‐field radiotherapy after four cycles of chemotherapy in patients with early‐stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(0732‐183X):3601‐8. ">Engert 2003</a>). Patients with Ann Arbor stage IIB and extranodal disease or bulky disease may be included in trials for advanced stages. </p> <p>Standard chemotherapy for early unfavourable and advanced stage HL in the USA is ABVD, a combination of adriamycin, bleomycin, vinblastine and dacarbazine (<a href="./references#CD007941-bbs2-0047" title="ChesonBD . What is new in lymphoma?. CA: A Cancer Journal for Clinicians2004;54:260‐72. ">Cheson 2004</a>). The ABVD regimen has less severe toxic effects on bone marrow than the previously used MOPP regimen (mechlorethamine, vincristine, procarbazine, and prednisone) and a non‐significant improvement in overall survival (OS) at five years compared to MOPP (66% for MOPP and 73% for ABVD) (<a href="./references#CD007941-bbs2-0044" title="CanellosGP , AndersonJR , PropertKJ , NissenN , CooperMR , HendersonES , et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. New England Journal of Medicine1992;327(0028‐4793 (Print), 21):1478‐84. ">Canellos 1992</a>). The problem after both therapy regimens is that there is a 30% to 35% risk of disease progression or relapse within five years and a poor response to salvage treatment (<a href="./references#CD007941-bbs2-0043" title="BonfanteV , SantoroA , VivianiS , DevizziL , BalzarottiM , SonciniF , et al. Outcome of patients with Hodgkin's disease failing after primary MOPP‐ABVD. Journal of Clinical Oncology1997;15(0732‐183X):528‐34. ">Bonfante 1997</a>; <a href="./references#CD007941-bbs2-0067" title="JostingA , FranklinJ , MayM , KochP , BeykirchMK , HeinzJ , et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2002;20(0732‐183X (Print), 1):221‐30. ">Josting 2002</a>). The ABVD regimen has a number of advantages: it is all‐intravenous, has less cumulative myelotoxicity, a lower risk of secondary malignancies and a lower rate of infertility compared with the previous regimen (<a href="./references#CD007941-bbs2-0047" title="ChesonBD . What is new in lymphoma?. CA: A Cancer Journal for Clinicians2004;54:260‐72. ">Cheson 2004</a>). </p> <p>In Germany, the standard treatment for early unfavourable and advanced stage HL was COPP/ABVD until the middle 1990s. Then, based on a mathematical model of tumour growth and chemotherapy effects predicting that moderate dose escalation would increase tumour control by 10% to 15% at five years (<a href="./references#CD007941-bbs2-0063" title="HasencleverD , LoefflerM , DiehlV . Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Annals of Oncology1996;7 Suppl 4(0923‐7534):95‐8. ">Hasenclever 1996</a>; <a href="./references#CD007941-bbs2-0071" title="LoefflerM , HasencleverD , DiehlV . Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Annals of Oncology1998;9 Suppl 5(0923‐7534 (Print)):S73‐8. ">Loeffler 1998</a>), the German Hodgkin Study Group (GHSG) evaluated tolerability and efficacy of a new regimen, BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) in time and dose intensification (<a href="./references#CD007941-bbs2-0053" title="DiehlV , SteinH , HummelM , ZollingerR , ConnorsJM . Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology: American Society of Hematology Education Program2003, issue 1520‐4391:225‐47. ">Diehl 2003</a>). After a median observation time of seven years, this study showed the superiority of the escalated BEACOPP regimen in comparison to COPP/ABVD in terms of freedom from treatment failure (85% versus 67%) and overall survival (90% versus 79%). However, an increased second leukaemia rate ((acute myeloid leukaemia (AML)/myeloid dysplastic syndrome (MDS)) was associated with the escalated BEACOPP regimen (<a href="./references#CD007941-bbs2-0054" title="DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease. New England Journal of Medicine2003;348(1533‐4406):2386‐95. ">Diehl 2003a</a>; <a href="./references#CD007941-bbs2-0055" title="DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11:307. ">Diehl 2004</a>). </p> </section> <section id="CD007941-sec-0039"> <h3 class="title" id="CD007941-sec-0039">Description of the intervention</h3> <p>This escalated BEACOPP schedule initiated by the GHSG in the late 1990s combines a shorter time (shorter cycle) and increased dose (increased single dose) scheme with the following substances: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone. The regimen should have been applied in an escalated dose, which is given in the Additional tables, <a href="#CD007941-tbl-0002">Table 1</a> (<a href="./references#CD007941-bbs2-0053" title="DiehlV , SteinH , HummelM , ZollingerR , ConnorsJM . Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology: American Society of Hematology Education Program2003, issue 1520‐4391:225‐47. ">Diehl 2003</a>) and a cycle should have been repeated after 21 days. As supportive therapy, granulocyte‐colony stimulating factor (G‐CSF) should have been administered during the escalated BEACOPP regimen from day eight of the cycle (Additional tables, <a href="#CD007941-tbl-0002">Table 1</a>). </p> <div class="table" id="CD007941-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">The escalated BEACOPP regimen</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single Dose (mg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Route</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days given*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleomycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Etoposide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxorubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclophosphamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vincristine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Procarbazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P.O.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P.O.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G‐CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>from day 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>*the regimen was repeated on day 22</p> <p>IV: intravenously, P.O.: orally, SC: subcutaneous</p> </td> </tr> </tbody> </table> </div> <p>We considered treatment with chemotherapy including ABVD regimen with or without radiotherapy as control condition<b>.</b> The ABVD regimen includes the following drugs: doxorubicin (adriamycin), bleomycin, vinblastine, and dacarbazine. A cycle should have been repeated after 28 days. The chemotherapy of the comparator arm should have included at least four cycles of ABVD. </p> <p>If additional radiotherapy was applied, the condition (based on remission status), dosage as well as field (involved or extended) must have been the same in both control and intervention arms. Supportive care should have been similar between control and intervention arms. </p> </section> <section id="CD007941-sec-0040"> <h3 class="title" id="CD007941-sec-0040">How the intervention might work</h3> <p>For people with early unfavourable HL, the investigation of more intensive chemotherapy regimens is an approach to improve long‐term results. The GHSG recommends to treat people with early unfavourable stages with four cycles of chemotherapy (e.g. two cycles escalated BEACOPP followed by two cycles ABVD). People in advanced stages should receive four to six cycles of escalated BEACOPP followed by two to four cycles of standard BEACOPP. </p> <p>The ABVD regimen is considered as standard therapy for people with HL in some study groups (e.g. the Southwest Oncology Group considered in the trial E2496 eight cycles of ABVD as standard therapy). This regimen is widely used because it is well‐proven, supported by phase III data from the 1990s and it is well‐tolerated and easy to administer. It is effective for patients with early unfavourable or advanced stage without inducing too many adverse events (<a href="./references#CD007941-bbs2-0061" title="GobbiPG , LevisA , ChisesiT , BrogliaC , VitoloU , StelitanoC , et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate‐ and advanced‐stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. Journal of Clinical Oncology2005;23(0732‐183X (Print), 36):9198‐207. ">Gobbi 2005</a>). </p> </section> <section id="CD007941-sec-0041"> <h3 class="title" id="CD007941-sec-0041">Why it is important to do this review</h3> <p>The most important challenge in treating HL is to find the optimal treatment that accomplishes the best efficacy with least toxicity (<a href="./references#CD007941-bbs2-0049" title="ConnorsJM , NoordijkEM , HorningSJ . Hodgkin's lymphoma: basing the treatment on the evidence. Hematology: American Society of Hematology Education Program2001, issue 1520‐4391:178‐93. ">Connors 2001</a>; <a href="./references#CD007941-bbs2-0050" title="ConnorsJM . State‐of‐the‐art therapeutics: Hodgkin's lymphoma. Journal of Clinical Oncology2005;23(0732‐183X):6400‐8. ">Connors 2005a</a>). So far there are two different standards for the treatment of early unfavourable staged and advanced staged HL. Chemotherapy with the ABVD regimen is widely used in North America (<a href="./references#CD007941-bbs2-0045" title="CanellosGP . Clinical trials in North America. European Journal of Haematology. Supplementum.2005, issue 0902‐4506 (Print), 66:121‐4. ">Canellos 2005a</a>), while chemotherapy with escalated BEACOPP regimen is mostly used in Germany and some other parts of Europe. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007941-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007941-sec-0042"></div> <p>To determine the advantages and disadvantages of chemotherapy including escalated BEACOPP compared to chemotherapy including ABVD in the treatment of early unfavourable or advanced stage Hodgkin lymphoma (HL). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007941-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007941-sec-0043"></div> <section id="CD007941-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007941-sec-0045"> <h4 class="title">Types of studies</h4> <p>We considered only randomised controlled trials (RCT) as primary studies in this review and meta‐analysis (<a href="./references#CD007941-bbs2-0073" title="O'ConnorD , GreenS , HigginsJPT . Chapter 5: Defining the review question and developing criteria for including studies. In: Higgins JPT GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">O'Connor 2011</a>). We included both full text and abstract publications. </p> </section> <section id="CD007941-sec-0046"> <h4 class="title">Types of participants</h4> <p>We included studies on male and female patients with previously untreated and histologically‐confirmed diagnosis of early unfavourable or advanced stage Hodgkin lymphoma (HL). We would have accepted trials with protocols for children as well as adults, but we could not identify any randomised trials including children. </p> <p>If the trial population had been mixed, including participants with haematological malignancies, we would have used data from the HL subgroup. If subgroups had been available (not reported and not provided after personally contacting the author), we would have included only trials with a minimum of 80% of patients with HL, but we could not identify any trial of this type. </p> <p>We included trials for early unfavourable or advanced stage HL. We considered patients with Ann Arbor stage I/II with risk factors as early unfavourable and patients with Ann Arbor stage III/IV independently from risk factors as advanced stages. We accepted the risk factors used by the respective study group or institution and kept the classification defined and used by the respective study group or institution. </p> </section> <section id="CD007941-sec-0047"> <h4 class="title">Types of interventions</h4> <p>To assure equal doses of chemotherapy, we considered chemotherapy including at least two cycles of escalated BEACOPP as the intervention condition, and regimens including at least four cycles of ABVD as the control condition, both with or without radiotherapy as first‐line treatment for early unfavourable or advanced stage HL (<a href="./references#CD007941-bbs2-0064" title="HasencleverD , BrosteanuO , GerikeT , LoefflerM . Modelling of chemotherapy: the effective dose approach. Annals of Hematology2001;80 Suppl 3:B89‐94. ">Hasenclever 2001</a>). </p> <p>We did not consider chemotherapy with BEACOPP given in the standard dose in this systematic review because the GHSG HD9 trial showed clearly better progression‐free survival (PFS) results with the escalated regimen (<a href="./references#CD007941-bbs2-0055" title="DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11:307. ">Diehl 2004</a>). </p> <p>If additional radiotherapy was applied, the condition, dosage and field should have been the same in both control and intervention arms. </p> </section> <section id="CD007941-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD007941-sec-0049"> <h5 class="title">Primary outcomes</h5> <p>As primary outcomes we chose overall survival (OS) and progression‐free survival (PFS). The definition of OS was time from randomisation until death as a result of any cause (<a href="./references#CD007941-bbs2-0048" title="ChesonBD , PfistnerB , JuweidME , GascoyneRD , SpechtL , HorningSJ , et al. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology2007;25(1527‐7755):579‐86. ">Cheson 2007a</a>). </p> <p>PFS was defined as the time from randomisation until disease progression, relapse or death as a result of any cause. PFS was provided by <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>, <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a> and <a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a>. However, we also accepted other definitions that addressed progression in the process of the disease such as freedom from treatment failure (FFTF) and event‐free survival (EFS). Freedom from treatment failure was defined as the time from randomisation until progression during treatment, lack of complete response at the end of treatment, relapse and death from any cause (<a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>). The definition of EFS was time from randomisation to evidence of severe toxicity causing definite treatment discontinuation, progressive lymphoma, cardiorespiratory failure, secondary leukaemia, death due to any cause, whichever occurred first (<a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>). Within the review, data coming under these definitions were discussed as results of PFS. </p> </section> <section id="CD007941-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p>In the previous version of this review the authors selected complete response (CR) rate as a secondary outcome because the endpoint is directly measuring the response to the therapy and is one of the outcomes often evaluated in clinical trials in oncology. The review authors also analysed other tumour control outcomes such as freedom from first progression defined as time from randomisation to first evidence of progressive lymphoma (<a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>). In this updated version, we considered these endpoints as less patient‐relevant ones, therefore, we did not present the results for these outcomes in the <a href="./full#CD007941-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>Other secondary outcomes were harms. We evaluated the following parameters for this purpose: </p> <p> <ul id="CD007941-list-0001"> <li> <p>treatment‐related mortality;</p> </li> <li> <p>secondary malignancies, particularly myeloid dysplastic syndrome (MDS) and acute myeloid leukaemia (AML); </p> </li> <li> <p>infertility (since infertility is only measurable indirectly, all assessed outcomes with respect to infertility are reported in the review); </p> </li> <li> <p>adverse events: haematological grade III or IV toxicity, assessed according to the WHO‐scale, particularly thrombocytopenia, leucopenia, anaemia and infection; </p> </li> <li> <p>adverse events: cardiopulmonary toxicity: pulmonary toxicity (bleomycin‐induced lung fibrosis). </p> </li> </ul> </p> <p>We additionally assessed quality of life in this updated review.</p> </section> </section> </section> <section id="CD007941-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <p>We adapted search strategies from those suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007941-bbs2-0069" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. ">Lefebvre 2008</a>). We applied no language restriction to reduce the language bias. </p> <section id="CD007941-sec-0052"> <h4 class="title">Electronic searches</h4> <p>For the primary review published in 2011 we searched the following databases in two steps: </p> <p>First step: MEDLINE (1985 to November 2008, search strategy see <a href="./appendices#CD007941-sec-0092">Appendix 1</a>), Embase (1985 to November 2008, search strategy see <a href="./appendices#CD007941-sec-0093">Appendix 2</a>) and Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library 2008, Issue 3, search strategy see <a href="./appendices#CD007941-sec-0094">Appendix 3</a>). </p> <p>Second step: In 2010 we adapted the search strategies and performed another search in MEDLINE (November 2008 to August 2010, search strategy see <a href="./appendices#CD007941-sec-0095">Appendix 4</a>) and CENTRAL (the Cochrane Library 2010 issue 8, search strategy see <a href="./appendices#CD007941-sec-0096">Appendix 5</a>). The Embase search was not updated because our account for this database ended in the meantime. </p> <p>To keep the review up to date we used the adapted search strategies and performed another search in MEDLINE (August 2010 to March 2017, search strategy see <a href="./appendices#CD007941-sec-0097">Appendix 6</a>) and CENTRAL (the Cochrane Library 2017 issue 03, search strategy see <a href="./appendices#CD007941-sec-0098">Appendix 7</a>). </p> </section> <section id="CD007941-sec-0053"> <h4 class="title">Searching other resources</h4> <p>For the primary review, we conducted the search for the years 1990 until August 2010. We searched those years which were included in CENTRAL via CENTRAL. For the updated review we searched the conference proceedings of annual meetings of the following societies for abstracts:         </p> <p> <ul id="CD007941-list-0002"> <li> <p>American Society of Clinical Oncology (ASCO) (up to the issue of 2016);</p> </li> <li> <p>American Society of Hematology (ASH) (up to the issue of 2016);      </p> </li> <li> <p>European Hematology Association (EHA) (up to the issue of 2016);       </p> </li> <li> <p>International Symposium on Hodgkin Lymphoma (ISHL) (up to the issue of 2016).  </p> </li> </ul> </p> <p>Moreover, we tried to identify trials with the following methods.      </p> <p> <ul id="CD007941-list-0003"> <li> <p>Handsearching of references</p> <ul id="CD007941-list-0004"> <li> <p>Citations from identified trials and relevant review articles.</p> </li> </ul> </li> </ul> <ul id="CD007941-list-0005"> <li> <p>We checked references of all identified trials, relevant review articles and current treatment guidelines for further literature. </p> </li> </ul> <ul id="CD007941-list-0006"> <li> <p>Personal contacts</p> <ul id="CD007941-list-0007"> <li> <p>We contacted experts in the field in order to locate other trials.</p> </li> </ul> </li> </ul> <ul id="CD007941-list-0008"> <li> <p>Databases of ongoing trials:</p> <ul id="CD007941-list-0009"> <li> <p>Meta‐register of controlled trials: <a href="http://www.controlled-trials.com/mrct/" target="_blank">http://www.controlled‐trials.com/mrct/</a> </p> </li> </ul> </li> </ul> <ul id="CD007941-list-0010"> <li> <p>We also searched a number of databases and websites of relevant institutions, agencies, organisations (e.g. study groups), societies and registries for (ongoing) trials (August 2016): </p> </li> </ul> <ul class="plain" id="CD007941-list-0011"> <li> <ul id="CD007941-list-0012"> <li> <p>Register of controlled trials: www.controlled‐trials.com</p> </li> <li> <p>EU clinical trials register: www.clinicaltrialsregister.eu/ctr‐search/search</p> </li> <li> <p>Clinicaltrials.gov: clinicaltrials.gov</p> </li> <li> <p>www.eortc.be</p> </li> <li> <p>www.ghsg.org</p> </li> <li> <p>www.ctc.usyd.edu.au</p> </li> <li> <p>www.trialscentral.org/index.html</p> </li> </ul> </li> </ul> </p> </section> </section> <section id="CD007941-sec-0054"> <h3 class="title" id="CD007941-sec-0054">Data collection and analysis</h3> <section id="CD007941-sec-0055"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AW, NS) independently screened titles and abstracts of studies identified from the sources listed above for potentially relevant studies. First, we screened and discarded studies that were clearly ineligible. We assessed selected studies with an eligibility form to determine whether they met the inclusion criteria. We resolved any disagreement between the two review authors by discussion. We would have sought further information from the authors, whose articles contained insufficient data to make a decision about eligibility. The eligibility form contained the following questions. </p> <p> <ul id="CD007941-list-0013"> <li> <p>Is the study described as a randomised trial for patients?</p> </li> <li> <p>Were the participants newly diagnosed with early unfavourable or advanced stage Hogdkin lymphoma? </p> </li> <li> <p>Were the participants in the intervention group treated with at least two cycles of escalated BEACOPP? </p> </li> <li> <p>Were the participants in the control group treated with at least four cycles of ABVD?</p> </li> </ul> </p> <p>To be eligible, studies had to meet all of the criteria stated above. We also identified duplicate reports. </p> <p>We obtained all full‐text versions of all eligible studies for quality assessment and data collection. At every stage of searching and screening of the literature, we documented the overall number of studies identified, excluded and included with reasons in a flow diagram (<a href="./references#CD007941-bbs2-0072" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: The PRISMA Statement. PLoS Medicine2009;6(7):e1000097. ">Moher 2009</a>). We resolved disagreements arising at any stage by discussion and consensus. If an agreement had not been reached, we would have asked a third review author (content expert) to give his or her opinion, in accordance with Chapter 7 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="https://archie.cochrane.org/sections/documents/view?version=z1512110318026010214423270818262%26format=REVMAN#REF-Higgins-2011" target="_blank">Higgins 2011</a>), but this procedure was not necessary. </p> </section> <section id="CD007941-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>We used both full‐text versions and abstracts (if full‐text was not published) of eligible studies to retrieve the data. In case these did not provide sufficient information, we contacted authors of individual studies for additional details (e.g. <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>; <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>; <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>). We conducted data extraction according to the guidelines proposed by Cochrane. For this review, two review authors (AW, NS) extracted data independently from the studies using a standardised data extraction form containing the following items. </p> <p> <ul id="CD007941-list-0014"> <li> <p>General information: first author of the publication, title of study, study ID, author's contact address (if available), source, publication date, country, language. </p> </li> <li> <p>Quality and 'Risk of bias' assessment: sequence generation, allocation concealment, blinding (participants, personnel, outcome assessors), incomplete outcome data, selective outcome reporting, other sources of bias. </p> </li> <li> <p>Trial details: trial design, objectives of the trial, types of outcomes reported, location, setting, sample size calculation, randomisation, treatment allocation, inclusion/exclusion criteria, reasons for exclusion, comparability of groups, length of follow‐up, stratification, stopping rules described, statistical analysis, results, power calculation, recruitment period, funding. </p> </li> <li> <p>Characteristics of participants: age, gender, ethnicity, total number recruited/randomised/analysed (total and for each arm), stage of the disease (Ann Arbor stage, B‐symptoms and risk factors), tumour response (if it was a criteria for randomisation), lost to follow‐up, dropouts by trial arm and reasons. </p> </li> <li> <p>Interventions: type of chemotherapy (name, dose and frequency of drugs from the chemotherapy regimen), number of cycles, length of a cycle and route of interventions, compliance to interventions, supportive therapy given, failure to maintain dose intensity, protocol violations, additional radiotherapy (dosage, field). </p> </li> <li> <p>Outcomes measured: overall survival (OS), progression‐free survival (PFS) or similar tumour control outcomes, treatment‐related mortality, secondary neoplasms (including overall secondary malignancies and AML and MDS), infertility, adverse events, especially haematological toxicity, cardiopulmonary toxicity, quality of life, response rate, freedom from treatment failure (FFTF), number of patients evaluated for each outcome, length of follow‐up for survival outcomes and definitions of the outcomes. </p> </li> </ul> </p> <p>We extracted trials reported in more than one publication on one form only. We resolved potential disagreements by consensus. If an agreement had not been reached, we would have asked a third review author (content expert) to give his or her opinion, but this procedure was not necessary. </p> </section> <section id="CD007941-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (AW, NS) assessed eligible studies obtained in the process of study selection as described above for methodological quality. To assess quality, we used the Cochrane 'Risk of bias' table. To improve transparency of judgements, we included quotations from the full‐text article or from supplemental information from the author in the notes section of the 'Risk of bias' table. </p> <p>We included the following items in the 'Risk of bias' assessment for randomised trials. For details of bias assessment we referred to Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007941-bbs2-0065" title="HigginsJPT , AltmanDG . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. ">Higgins 2011a</a>). </p> <p>There are three categories: yes (low risk of bias), unclear, and no (high risk of bias) in response to the following questions. </p> <p> <ul id="CD007941-list-0015"> <li> <p>Sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding (participants, personnel, outcome assessors)</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other potential sources of bias</p> </li> </ul> </p> </section> <section id="CD007941-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>For binary variables, we estimated treatment effect measures of individual studies as relative effect measures risk ratio (RR) with corresponding 95% confidence intervals by using the Mantel‐Haenszel method in a fixed‐effect model. For time‐to‐event variables, we estimated treatment effects as hazard ratio (HR) with corresponding 95% confidence intervals by using the generic inverse variance method in a fixed‐effect model. For each trial, we extracted information about time‐to‐event outcome using the methods described by Tierney (<a href="./references#CD007941-bbs2-0074" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>; <a href="./references#CD007941-bbs2-0081" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>). </p> </section> <section id="CD007941-sec-0059"> <h4 class="title">Dealing with missing data</h4> <p>We dealt with missing data as suggested in Chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007941-bbs2-0066" title="HigginsJPT , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. ">Higgins 2011b</a>), We contacted the original investigators to request missing data and received additional information from Mournier and colleagues. We performed sensitivity analysis to assess how sensitive results were to reasonable changes in the assumptions that had been made. We addressed the potential impact of missing data on the findings of the review in the discussion. </p> </section> <section id="CD007941-sec-0060"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity of treatment effects between trials by using a Chi<sup>2</sup> test with a significance level at P &lt; 0.1. We used the I² statistic to quantify possible heterogeneity (30% &lt; I² &lt; 75%: moderate heterogeneity, 75% &lt; I²: considerable heterogeneity) (<a href="./references#CD007941-bbs2-0051" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses.. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. ">Deeks 2011</a>). </p> <p>We explored potential causes of heterogeneity by performing sensitivity and subgroup analysis. </p> </section> <section id="CD007941-sec-0061"> <h4 class="title">Assessment of reporting biases</h4> <p>In a meta‐analysis with more than 10 trials, we would have explored potential reporting bias by generating a funnel plot and statistically testing this by conducting a linear regression test (<a href="./references#CD007941-bbs2-0078" title="SterneJAC , EggerM , MoherD . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editors(s). In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. ">Sterne 2011</a>). A P value less than 0.1 would have been considered significant for this test. However, we only included five trials so this test was not done. </p> </section> <section id="CD007941-sec-0062"> <h4 class="title">Data synthesis</h4> <p>According to the recommendations of Cochrane (<a href="https://archie.cochrane.org/sections/documents/view?version=z1510091437463297608510967575742%26format=REVMAN#REF-Deeks-2011" target="_blank">Deeks 2011</a>), we performed meta‐analyses by using a fixed‐effect model (i.e. generic inverse variance method for time‐to‐event outcomes and a Mantel‐Haenszel method for dichotomous outcomes). </p> <p>We performed analyses according to the recommendations of Cochrane using the Review Manager (<a href="./references#CD007941-bbs2-0075" title="The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. The Nordic Cochrane Centre. Version 5.3. Copenhagen. The Cochrane Collaboration, 2014. ">Review Manager 5.3</a>) and listed the predefined outcomes OS, PFS, the adverse events treatment‐related mortality, secondary malignancies, secondary AML/ MDS, and infertility, and quality of life in a 'Summary of findings' table <a href="./full#CD007941-tbl-0001">summary of findings Table for the main comparison</a> on absolute risks in each group with the help of <a href="./references#CD007941-bbs2-0062" title="McMaster University. GRADEpro. McMaster University, 2015. ">GRADE pro 2014</a>. </p> </section> <section id="CD007941-sec-0063"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to take the following parameters into consideration for subgroup analysis of the primary outcomes: </p> <p> <ul id="CD007941-list-0016"> <li> <p>stage of the disease (early unfavourable versus advanced);</p> </li> <li> <p>age (e.g. children versus adults ≤ 50 years versus adults &gt; 50 years, or depending on the median age of the trial); </p> </li> <li> <p>treatment regimens (i.e. only ABVD regimen versus chemotherapy including ABVD regimen);</p> </li> <li> <p>length of therapy (e.g. four versus eight cycles of chemotherapy);</p> </li> <li> <p>number of cycles of escalated BEACOPP (i.e. two versus four versus eight);</p> </li> <li> <p>radiotherapy (with or without radiotherapy);</p> </li> <li> <p>sequence (e.g. BEACOPP followed by other agents versus other chemotherapeutic agents followed by BEACOPP); </p> </li> <li> <p>length of follow‐up (i.e. long follow‐up (more than five years) versus short follow‐up (five years or less); </p> </li> <li> <p>same total number of cycles of chemotherapy for the control and intervention groups (yes versus no). </p> </li> </ul> </p> <p>We did not conduct planned subgroup analysis by "age", "length of therapy", "sequence", and "total number of cycles of chemotherapy" because the included studies were similar with regard to these characteristics. </p> <p>We did a test for subgroup differences and considered a P‐value of less than 0.05 as statistical significant for all the outcomes mentioned in the 'Summary of findings' table. </p> </section> <section id="CD007941-sec-0064"> <h4 class="title">Sensitivity analysis</h4> <p>We would have assessed robustness of the results of the primary outcomes by analyses of the kind of publication (full‐text publications/abstracts) and the type of results (preliminary results/mature results). However, all included trials have been published as full texts. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007941-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007941-sec-0065"></div> <section id="CD007941-sec-0066"> <h3 class="title">Description of studies</h3> <section id="CD007941-sec-0067"> <h4 class="title">Results of the search</h4> <p>In total, we screened 790 for the primary review and for the updated version 1006 potentially relevant records up to March 2017 (1796 references after duplicates removed). Of these, 1706 were excluded at the initial stage of screening because they did not fulfil our predefined inclusion criteria. The remaining 90 publications were retrieved as full‐text publications or abstract publications for detailed evaluation. Of these 90 references, 37 were excluded. Five eligible trials (all published) were identified and finally all five trials (53 publications) with 3427 patients were formally included in the main analyses of this review (see <a href="#CD007941-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD007941-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007941-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD007941-sec-0068"> <h4 class="title">Included studies</h4> <p>Five trials (<a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a>; <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>; <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>; <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>) were included in the review. We extracted data from full‐text publications for all five trials. Furthermore, we received additional information from Gianni and colleagues and Borchmann and colleagues to complete the outcome data as well as additional information of patient characteristics of the published abstracts. </p> <p>See also the table <a href="./references#CD007941-sec-0108" title="">Characteristics of included studies</a>. </p> <p><b>Design</b> </p> <p>Of the five included trials, three trials were two‐armed randomised controlled trials (<a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a>; <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>; <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>) and two trials were three‐armed randomised controlled trials (<a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>). One of these trials recruited patients from 1993 to 1998 (<a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>), and the others within a period between 2000 to 2008. </p> <p><b>Participants</b> </p> <p>A total of 4124 patients with newly confirmed diagnosis of early unfavourable (<a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a> N = 1655) or advanced stage HL (<a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a> N = 549; <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a> N = 1282; <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a> N = 331; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a> N = 307) were randomised within the five trials, but only 3427 of these could be included in this review as they received regimens including escalated BEACOPP or ABVD (<a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a> N = 549; <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a> N = 727; <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a> N = 1623; <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a> N = 3142; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a> N = 197).<br/> <br/> All five studies had different eligibility criteria for age (<a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a>: 16 to 60 years <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>: 16 to 65 years; <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>: 16 to 60 years; <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>: up to 60 years of age; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>: older than 16 years of age. Only three trials reported data regarding the median age of included patients in these studies (<a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a>: 35.2 years; <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>: 32 years; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>: 29 years). The proportion of the patients being older than 45 or 50 years was between 15% to 26% in the three reporting trials (<a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>: escalated BEACOPP: 15% of 466 patients 50 to 65 years old; standard BEACOPP: 18% of 469 patients 50 to 65 years old; COPP/ABVD: 16% of 260 patients 50 to 65 years old; <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>: escalated BEACOPP 20% of 155 patients at least 45 years; ABVD 23% of 166 patients at least 45 years); <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>: escalated BEACOPP: 17% of 98 patients at least 45 years); CEC: 26% of 98 patients at least 45 years; ABVD: 18% of 99 patients at least 45 years. </p> <p><b>Location</b> </p> <p>The included trials were co‐ordinated from Europe. Two were performed by the German Hodgkin Study Group (<a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>; <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>), two others were provided by Italian study groups (<a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>), the <a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a> trial had its headquarter in Belgium. </p> <p><b>Intervention</b> </p> <p>Patients from the included trials were either treated with chemotherapy including escalated BEACOPP or with chemotherapy including ABVD as primary treatment for HL. The included trials used the following regimens: four escalated plus two standard courses of BEACOPP versus six courses of ABVD versus six courses of CEC (cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin) (<a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>); two escalated courses of BEACOPP plus two courses of ABVD versus four courses of ABVD (<a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>), eight escalated courses of BEACOPP versus eight courses of cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) alternating with ABVD (<a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>), four escalated plus four standard courses of BEACOPP versus six to eight courses of ABVD <a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a> and <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>. Three of these trials scheduled radiotherapy after chemotherapy for sites of previous bulky disease and slowly or partially responding sites with 30 to 40 Gray (<a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>; <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>). In the <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a> trial, all patients received involved‐field radiotherapy of 30 Gray. In the <a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a> trial, none of the patients had received radiotherapy. </p> <section id="CD007941-sec-0069"> <h5 class="title">Outcomes</h5> <section id="CD007941-sec-0070"> <h6 class="title">Primary outcome measure</h6> <p>All included trials analysed overall survival (OS). The median observation times for OS were as follows: 10 years for two trials (<a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>), however, as no hazard ratios (HRs) were provided for <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>, only the short‐term data could be analysed. The median observation time was six years for one trial (<a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>); three to 3.5 years for two trials (<a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a>; <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>). Progression‐free survival (PFS) or similar outcomes (for further information see '<a href="#CD007941-sec-0048">Types of outcome measures</a>, <a href="#CD007941-sec-0049">Primary outcomes</a>') were analysed by all included trials. The median observation times for these outcomes were the same as for OS. </p> </section> <section id="CD007941-sec-0071"> <h6 class="title">Secondary outcome measures</h6> <p>Four trials (<a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a>; <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>; <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>) reported complete response (CR) rates. Analysable information with regard to adverse events was reported by the following studies: haematological grade III or IV toxicity by three studies (<a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>; <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>), secondary malignancies by three studies (<a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>; <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>), treatment‐related mortality was reported by one study (<a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>), and respiratory toxicity by one study (<a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>). Time to progression was reported by one study (<a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>) and data regarding infertility was reported only by one study (<a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>). </p> </section> </section> </section> <section id="CD007941-sec-0072"> <h4 class="title">Excluded studies</h4> <p>A total of 37 articles were excluded after detailed evaluation of full‐text publications. The main reasons for exclusion were: </p> <p> <ul id="CD007941-list-0017"> <li> <p>24 non‐randomised comparisons or reviews;</p> </li> <li> <p>14 did not evaluate escalated BEACOPP versus ABVD.</p> </li> </ul> </p> <p>These publications are described under <a href="./references#CD007941-sec-0109" title="">Characteristics of excluded studies</a>. </p> <p><b>Ongoing studies</b> </p> <p>The only ongoing study noticed in the primary review, <a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a> , has been published and included in this review. We could not identify any further ongoing trial addressing the objective of this review. </p> </section> </section> <section id="CD007941-sec-0073"> <h3 class="title">Risk of bias in included studies</h3> <p>Further details on the 'Risk of bias' assessment are shown in Figure 2 and <a href="#CD007941-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD007941-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007941-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD007941-sec-0074"> <h4 class="title">Allocation</h4> <p>The <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a> and <a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a> trials reported that treatment allocation of patients was performed at a central trials office and sequence was generated by computer (low risk of bias). The other trials did not state any information with respect to these issues, therefore we judged as unclear risk of bias. </p> </section> <section id="CD007941-sec-0075"> <h4 class="title">Blinding</h4> <p>None of the trials reported information about blinding. Results with respect to OS are judged not to be influenced by this source of bias, because to define the status of a patient as dead or alive is not a question of individual judgement. With regard to the remaining outcomes all trials were judged "high" for the question of blinding, as it is known that blinding is not feasible in this setting and might influence the outcomes. </p> </section> <section id="CD007941-sec-0076"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>, <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a> and <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a> described missing outcome data in detail. The <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a> trial excluded 80 patients because they did not fulfil the inclusion criteria of the study and five patients due to other reasons. <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a> excluded all in all eight patients. Missing outcome data in both trials were balanced in numbers across intervention groups (see 'Risk of bias' tables for further details). <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a> did not include 32 of 1655 patients in the analyses, but missing outcome data were balanced in numbers across both groups (see 'Risk of bias' tables for further details). <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a> and <a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a> analysed all randomised patients. However, due to the small proportion of missing data in most trials and the detailed descriptions in two of them, we do not believe that bias was introduced into the meta‐analysis by missing data. Therefore we judged attrition bias "low" for all studies. </p> </section> <section id="CD007941-sec-0077"> <h4 class="title">Selective reporting</h4> <p>As all the outcomes are reported for the <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a> trials as published in the protocol, we judge the risk of bias as low. <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a> is registered in a clinical study registry, but no outcomes are reported, therefore we judge the potential risk of bias as unclear. We could not identify protocols for <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a> and <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a> and judge the risk of bias as being unclear. In the study registry it is mentioned that <a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a> evaluated quality of life, but this outcomes is not published, therefore we judge potential risk of bias as high. </p> </section> <section id="CD007941-sec-0078"> <h4 class="title">Other potential sources of bias</h4> <p>In the <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a> trial, randomisation to the escalated BEACOPP arm started later than the randomisation to the ABVD arm and the standard BEACOPP arm. Furthermore, randomisation to the COPP/ABVD arm was stopped after the first interim analysis due to the fact that both BEACOPP groups together were significantly superior to COPP/ABVD in terms of the rate of freedom from treatment failure (FFTF) (<a href="./references#CD007941-bbs2-0053" title="DiehlV , SteinH , HummelM , ZollingerR , ConnorsJM . Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology: American Society of Hematology Education Program2003, issue 1520‐4391:225‐47. ">Diehl 2003</a>). According to this potential risk of bias, the analyses of OS and PFS were based on data of patients recruited within the same time period. J. Franklin, statistician for the HD9 trial, recalculated HRs with confidence intervals (CI) for OS und PFS by considering only patients who where randomised in the same time‐period (between date 1 and date 2). He had a direct access to the individual patient data. It means he considered 265 patients for the escalated BEACOPP arm and 177 patients for the COPP/ABVD arm. We generally judged the risk of other potential sources as "unclear". </p> <p>The <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a> trial was initially designed to examine the myelotoxicity of CEC and BEACOPP regimens compared to ABVD, but the protocol was amended after the first 18 months to test the effect of BEACOPP regimen versus ABVD and CEC, respectively. To calculate the power of the study a one‐sided test was used to consider the expected superiority of BEACOPP in terms of failure‐free survival (FFS). To use a one‐sided test might have led to an underpowered design of the study which leads to an estimate of "high" risk. </p> </section> </section> <section id="CD007941-sec-0079"> <h3 class="title" id="CD007941-sec-0079">Effects of interventions</h3> <p>See: <a href="./full#CD007941-tbl-0001"><b>Summary of findings for the main comparison</b> Escalated BEACOPP versus chemotherapy including ABVD</a> </p> <p><b>Primary outcome: overall survival (OS)</b> </p> <p><i>Participants</i> <br/> All five trials provided information regarding this outcome. To avoid the introduction of potential risk of bias that might have been caused by the <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a> trial, patients of this trial had to be recruited in a parallel time period to be considered in the analyses (<a href="#CD007941-sec-0078">Other potential sources of bias</a>). Together with the patients randomised in the four other trials, this analysis included 3142 participants. </p> <p><i>Results</i> <br/> In the main analysis, there was a statistically significant difference between treatment with escalated BEACOPP or ABVD on OS favouring BEACOPP: hazard ratio (HR) 0.74 (95% confidence interval (CI) 0.57 to 0.97, P = 0.03). There was no statistical heterogeneity between the trials, with an I<sup>2</sup> = 0% (see <a href="#CD007941-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD007941-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Analysis of Overall Survival, outcome: 1.1 OS ‐ all ‐ same recruitment period between the 2 arms (HD9)." data-id="CD007941-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Analysis of Overall Survival, outcome: 1.1 OS ‐ all ‐ same recruitment period between the 2 arms (HD9). </p> </div> </div> </div> <p><i>Subgroup analysis</i> </p> <p>We conducted subgroup analysis to explore the underlying clinical heterogeneity in order to assess the influence of clinical differences between the studies. </p> <p>The "test for subgroup differences" showed no statistical differences between the following subgroups: </p> <p> <ul id="CD007941-list-0018"> <li> <p>different stages of disease (P = 0.28, early unfavourable: one trial, N = 1623; advanced: four trials, N = 1519); <a href="./references#CD007941-fig-0006" title="">Analysis 1.2</a> </p> </li> <li> <p>different types of treatment regimens (P = 0.29, only ABVD: four trials, N = 2700; ABVD including regimen: one trial, N = 442); <a href="./references#CD007941-fig-0007" title="">Analysis 1.3</a> </p> </li> <li> <p>different numbers of cycles of escalated BEACOPP (P = 0.43, eight cycles: one trial, N = 442; four cycles: three trials, N = 1077; two cycles: one trial, N = 1623); <a href="./references#CD007941-fig-0008" title="">Analysis 1.4</a> </p> </li> <li> <p>different length of follow‐up (P = 0.29, short‐term follow‐up: four trials, N = 2700, long‐term follow‐up: one trial, N = 442); <a href="./references#CD007941-fig-0009" title="">Analysis 1.5</a> </p> </li> <li> <p>radiotherapy: (P = 0.84, without radiotherapy: one trial, N = 549; with radiotherapy: four trials, N = 2583); <a href="./references#CD007941-fig-0010" title="">Analysis 1.6</a>. </p> </li> </ul> </p> <p>Subgroup analyses in terms of "age", "length of therapy", "sequence", and "same total number of cycles of chemotherapy" were not performed, because the identified studies showed no differences due to these study characteristics (see <a href="#CD007941-sec-0063">Subgroup analysis and investigation of heterogeneity</a>). </p> <p><i>Sensitivity analysis</i> </p> <p>We also performed a sensitivity analysis for all recruited patients with potential risk of bias due to different time periods of recruitment in <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>. This analysis showed also statistically significant effect favouring BEACOPP escalated (HR 0.66, 95% CI 0.52 to 0.84, N = 3427); <a href="./references#CD007941-fig-0011" title="">Analysis 1.7</a>. </p> <p><b>Primary outcome: progression‐free survival</b> </p> <p><i>Participants</i> <br/> All five trials provided information regarding this outcome. Similar to the procedure for participants of OS, we used the data of patients who were recruited in the <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a> trial in parallel with the other three trials to perform the main analysis of PFS. This was to avoid the introduction of potential risk of bias (<a href="#CD007941-sec-0078">Other potential sources of bias</a>). This analyses included data of 3142 patients from all five studies. </p> <p><i>Results</i> </p> <p>The main analysis of PFS showed a statistically significant improved outcome for patients with escalated BEACOPP: HR was 0.54 (95% CI 0.45 to 0.64), see <a href="#CD007941-fig-0004">Figure 4</a>. There was no heterogeneity between trials (I<sup>2</sup> = 0%). </p> <div class="figure" id="CD007941-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Analysis of Progression Free Survival, outcome: 2.1 PFS ‐ all ‐ same recruitment period between the 2 arms (HD9)." data-id="CD007941-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Analysis of Progression Free Survival, outcome: 2.1 PFS ‐ all ‐ same recruitment period between the 2 arms (HD9). </p> </div> </div> </div> <p><i>Subgroup analysis</i> </p> <p>We conducted subgroup analysis to explore the potential underlying clinical heterogeneity between the studies. The "test for subgroup differences" showed no statistical differences between the following subgroups: </p> <p> <ul id="CD007941-list-0019"> <li> <p>different stages of disease (P = 0.47, early unfavourable: one trial, N = 1623; advanced: four trials, N = 1519); <a href="./references#CD007941-fig-0013" title="">Analysis 2.2</a> </p> </li> <li> <p>different types of treatment regimens (P = 0.62, only ABVD: four trials, N = 2700; ABVD including regimen: one trial, N = 442); <a href="./references#CD007941-fig-0014" title="">Analysis 2.3</a> </p> </li> <li> <p>different numbers of cycles of escalated BEACOPP (P = 0.61, eight cycles: one trial, N = 442; four cycles: three trials, N = 1077; two cycles: one trial, N = 1623); <a href="./references#CD007941-fig-0015" title="">Analysis 2.4</a> </p> </li> <li> <p>different length of follow‐up (P = 0.62, short‐term follow‐up: four trials, N = 2700; long‐term follow‐up: one trial, N = 442); <a href="./references#CD007941-fig-0016" title="">Analysis 2.5</a> </p> </li> <li> <p>radiotherapy: (P = 0.69, without radiotherapy: one trial, N = 549; with radiotherapy: four trials, N = 2593); <a href="./references#CD007941-fig-0017" title="">Analysis 2.6</a>. </p> </li> </ul> </p> <p>As explained above, subgroup analyses in terms of "age", "length of therapy", "sequence", and "same total number of cycles of chemotherapy" were not performed (see <a href="#CD007941-sec-0063">Subgroup analysis and investigation of heterogeneity</a>). </p> <p><i>Sensitivity analysis</i> </p> <p>We also performed a sensitivity analysis for all recruited patients with potential risk of bias due to different time periods of recruitment in <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>. This analysis showed also statistically significant effect favouring BEACOPP escalated (HR 0.51, 95% CI 0.43 to 0.60, N = 3427); <a href="./references#CD007941-fig-0018" title="">Analysis 2.7</a>. </p> <p><b>Secondary outcome: treatment‐related mortality</b> </p> <p><i>Participants</i> <br/> Data of the treatment‐related mortality was available from the four trials <a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a><a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>, <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a> and <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a> including 2700 participants. </p> <p><i>Results</i> </p> <p>Escalated BEACOPP showed no clear evidence for a difference in terms of treatment‐related mortality, but might be increased with BEACOPP escalated (four trials, N = 2700, (risk ratio (RR) 2.15, 95% CI 0.93 to 4.95) as shown in <a href="./references#CD007941-fig-0019" title="">Analysis 3.1</a> </p> <p>We conducted subgroup analysis to explore the potential underlying clinical heterogeneity between the studies. The "test for subgroup differences" showed no statistical differences between the following subgroups: </p> <p> <ul id="CD007941-list-0020"> <li> <p>different stages of disease (P = 0.28, early unfavourable: one trial, N = 1623; advanced: three trials, N = 1077); <a href="./references#CD007941-fig-0020" title="">Analysis 3.2</a> </p> </li> <li> <p>different numbers of cycles of escalated BEACOPP (P = 0.28, early unfavourable: one trial, N = 1623; advanced: three trials, N = 1077); <a href="./references#CD007941-fig-0021" title="">Analysis 3.3</a> </p> </li> </ul> </p> <p>The subgroup analysis for addition of radiotherapy showed a statistical significant subgroup difference (P = 0.04). We did not find evidence for a difference between both intervention arms, if no radiotherapy was applied (RR 0.84, 95% CI 0.26 to 2.71, one trial), but an advantage for the ABVD arm, if additional radiotherapy was administered (RR 6.13, 95% CI 1.38 to 27.26, three trials); <a href="./references#CD007941-fig-0022" title="">Analysis 3.4</a>. However, due to the low number of events results needs to be confirmed before final conclusions can be drawn. </p> <p><b>Secondary outcome: secondary malignancies</b> </p> <p><i>Participants</i> </p> <p>The number of secondary malignancies was reported by all trials (<a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a>; <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>; <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>; <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>), including 3332 patients. </p> <p><i>Results</i> </p> <p>There was no evidence for a difference between both regimens in terms of total rate of secondary malignancies (five trials, N = 3332, RR 1.00, 95% CI 0.68 to 1.48, P = 0.92); <a href="./references#CD007941-fig-0023" title="">Analysis 4.1</a> </p> <p>The "test for subgroup differences" showed no statistical differences between the following subgroups: different stages of disease, different types of treatment regimens, different numbers of cycles of escalated BEACOPP, different length of follow‐up and whether additional radiotherapy was applied (see <a href="./references#CD007941-fig-0024" title="">Analysis 4.2</a>; <a href="./references#CD007941-fig-0025" title="">Analysis 4.3</a>; <a href="./references#CD007941-fig-0026" title="">Analysis 4.4</a>; <a href="./references#CD007941-fig-0027" title="">Analysis 4.5</a>; <a href="./references#CD007941-fig-0028" title="">Analysis 4.6</a>). </p> <p><b>Secondary outcome: secondary AML or MDS</b> </p> <p><i>Participants</i> </p> <p>All trials (<a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a>; <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>;<a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>; <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>;<a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>) reported occurrence of MDS or AML, N = 3332. </p> <p><i>Results</i> </p> <p>There was a statistically significantly increased occurrence of MDS or AML in BEACOPP included regimens (five trials, N = 3332, RR 3.90, 95% CI 1.36 to 11.21, P = 0.02); <a href="./references#CD007941-fig-0029" title="">Analysis 5.1</a> </p> <p>We did not identify any statistical differences between the following subgroups: different stages of disease, different types of treatment regimens, different numbers of cycles of escalated BEACOPP, different length of follow‐up and whether additional radiotherapy was applied (see <a href="./references#CD007941-fig-0030" title="">Analysis 5.2</a>; <a href="./references#CD007941-fig-0031" title="">Analysis 5.3</a>; <a href="./references#CD007941-fig-0032" title="">Analysis 5.4</a>; <a href="./references#CD007941-fig-0033" title="">Analysis 5.5</a>; <a href="./references#CD007941-fig-0034" title="">Analysis 5.6</a>). </p> <p><b>Secondary outcome: infertility</b> </p> <p>Data regarding infertility were only applied for 106 women of the <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a> trial. </p> <p><i>Results</i> </p> <p>Secondary amenorrhoea was evaluated as a quantity of infertility, without evidence for a difference between both arms (one trial, N = 106, RR 1.37 0.83 to 2.26, P = 0.22); <a href="./references#CD007941-fig-0035" title="">Analysis 6.1</a> </p> <p>As only one trial was included, subgroup analyses were not possible</p> <p><b>Secondary outcome: adverse events</b> </p> <p><i>Participants</i> <br/> Data for the majority of acute adverse effects WHO grade III or IV (i.e. anaemia, infection, thrombocytopenia, mucositis, nausea/vomiting, neurologic toxicity, leucopenia, alopecia, pain) were reported by three trials (<a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>; <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>) including 2425 participants. Respiratory adverse events were reported by the <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>, <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a> and <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a> trial. The following adverse events were reported by two trials each: neutropenia (<a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>; N = 519), constipation (<a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>; N = 923), analysis of skin (<a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>; <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>; N = 2227) and heart (<a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>; <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>; N = 1823), </p> <p>Due to the low number of included trials we did not perform subgroup analyses.</p> <p><i>Results</i> </p> <p>The escalated BEACOPP regimen caused statistically significantly more acute adverse effects WHO grade III or IV in terms of: </p> <p> <ul id="CD007941-list-0021"> <li> <p>anaemia (three trials, N = 2425, RR 10.67, 95% CI 7.14 to 15.93, P &lt; 0.00001); <a href="./references#CD007941-fig-0036" title="">Analysis 7.1</a> </p> </li> <li> <p>infection (three trials, N = 2425, RR 3.73, 95% CI 2.58 to 5.38, P &lt; 0.00001); <a href="./references#CD007941-fig-0037" title="">Analysis 8.1</a> </p> </li> <li> <p>neutropenia (two trials, N = 519, RR 1.80, 95% CI 1.52 to 2.13, P &lt; 0.00001); <a href="./references#CD007941-fig-0038" title="">Analysis 9.1</a> </p> </li> <li> <p>thrombocytopenia (three trials, N = 2425, RR 18.12, 95% CI 11.77 to 27.92, P &lt; 0.00001); <a href="./references#CD007941-fig-0039" title="">Analysis 10.1</a> </p> </li> <li> <p>alopecia (three trials, N = 2425, RR 1.98 95% CI 1.78 to 2.21, P &lt; 0.00001); <a href="./references#CD007941-fig-0040" title="">Analysis 11.1</a> </p> </li> <li> <p>mucositis (three trials, N = 2425, RR 8.04, 95% CI 3.72 to 17.38, P = 0.0005); <a href="./references#CD007941-fig-0042" title="">Analysis 13.1</a> </p> </li> <li> <p>neurologic toxicity (three trials, N = 2425, RR 2.04, 95% CI 1.19 to 3.50, P = 0.009); <a href="./references#CD007941-fig-0044" title="">Analysis 15.1</a> </p> </li> <li> <p>acute adverse effect of the respiratory tract (three trials, N = 2549, RR 1.80, 95% CI 1.01 to 3.20, P = 0.05); <a href="./references#CD007941-fig-0046" title="">Analysis 17.1</a> </p> </li> <li> <p>pain (three trials, N = 2425, RR 2.62, 95% CI 1.76 to 3.90, P &lt; 0.00001); <a href="./references#CD007941-fig-0045" title="">Analysis 16.1</a> </p> </li> </ul> </p> <p>No statistically significant differences between escalated BEACOPP and ABVD‐like regimens were found for: </p> <p> <ul id="CD007941-list-0022"> <li> <p>constipation (two trials, N = 923, RR 1.19, 95% CI 0.56 to 2.55, P = 0.65); <a href="./references#CD007941-fig-0041" title="">Analysis 12.1</a> </p> </li> <li> <p>nausea/vomiting (three trials, N = 2425, RR 0.83, 95% CI 0.68 to 1.01, P = 0.06); <a href="./references#CD007941-fig-0043" title="">Analysis 14.1</a> </p> </li> <li> <p>effects on skin (two trials, N = 2227, RR 1.02 95% CI 0.45 to 2.34, P = 0.96); <a href="./references#CD007941-fig-0047" title="">Analysis 18.1</a> </p> </li> <li> <p>effects on heart (two trials, N = 1823, RR 1.04 95% CI 0.21 to 5.10, P = 0.96); <a href="./references#CD007941-fig-0048" title="">Analysis 19.1</a> </p> </li> </ul> </p> <p>One trial (<a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>) reported severe adverse events grade 3 or 4 split in haematological and non‐haematological events during initial chemotherapy. In the BEACOPP arm there were 81% (127/156) participants and in the ABVD arm 43% (72/166) participants affected with haematological events. Non‐haematological events could be seen in 19% (30/156) participants from the BEACOPP group and 7% (12/166) of the people belonging to the ABVD group. </p> <p>There were a number of adverse events which we did not evaluate in this review, however, these are presented in <a href="#CD007941-tbl-0003">Table 2</a>. </p> <div class="table" id="CD007941-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events (reported by two trials)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Name of trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Experimental arm (N)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control arm (N)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal, others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43/744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/757</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urogenital tract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/757</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drug fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/757</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allergy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/757</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal, others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fever of unknown reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/166</p> </td> </tr> </tbody> </table> </div> <p><b>Secondary outcome: quality of life</b> </p> <p>Quality of life was not reported by any of the included trials. One trial (<a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a>) stated in the study protocol that quality of life would be assessed, however, there are no results reported. </p> <p><b>Secondary outcome: complete response (CR) rate</b> </p> <p><i>Participants</i> <br/> CR rate data were available from five trials (<a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a>; <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>; <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>; <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>) that included 3427 participants. Data from the parallel randomisation period of the <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a> trial were not available so we used the provided CR results of all included patients of this trial. </p> <p><i>Results</i> <br/> The overall estimate of CR rate showed no evidence for a difference (RR 1.03, 95% CI 1.01 to 1.06, P = 0.01, I² = 0%) (see <a href="./references#CD007941-fig-0050" title="">Analysis 21.1</a>). </p> <p><b>Secondary outcome: freedom from first progression</b> </p> <p><i>Participants</i> <br/> Data of the freedom from first progression was only available from the <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a> trial with 331 participants. </p> <p><i>Results</i> </p> <p>There was a statistically significant evidence for a difference favouring escalated BEACOPP with regard to freedom from first progression (one trial, N = 331, RR 0.46, 95% CI 0.27 to 0.78, P = 0.004) see <a href="./references#CD007941-fig-0049" title="">Analysis 20.1</a>. </p> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007941-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007941-sec-0080"></div> <section id="CD007941-sec-0081"> <h3 class="title" id="CD007941-sec-0081">Summary of main results</h3> <p>In this systematic review we analysed the efficacy and safety of escalated BEACOPP and ABVD chemotherapies for the treatment of early unfavourable or advanced stage Hodgkin lymphoma (HL). The results are summarised in the <a href="./full#CD007941-tbl-0001">summary of findings Table for the main comparison</a>. The findings emerging from these meta‐analyses are as follows. </p> <p> <ul id="CD007941-list-0023"> <li> <p>In contrast to the first version of this review, the present meta‐analysis shows evidence for a difference in overall survival (OS), favouring BEACOPP escalated. </p> </li> <li> <p>The meta‐analysis also showed evidence for an improvement in progression‐free survival (PFS) for patients who received BEACOPP escalated. </p> </li> <li> <p>There is no evidence for a difference for treatment‐related mortality, but it might be higher with BEACOPP escalated. </p> </li> <li> <p>The meta‐analysis showed a statistically significant higher number of myeloid dysplastic syndrome (MDS) or acute myeloid leukaemia (AML in patients) with advanced HL treated with escalated BEACOPP, but there is no evidence for a difference for overall rate of secondary malignancies between the comparators. </p> </li> <li> <p>So far there is not enough evidence to judge the effects of both regimens on infertility. However, available data showed no evidence for a difference between the treatments in patients with advanced HL. </p> </li> <li> <p>Treatment with escalated BEACOPP presents evidence for an increase in haematological toxicities WHO grade III or VI, such as anaemia, neutropenia, thrombocytopenia, and infection and non‐haematological adverse events like alopecia, mucositis and pain. </p> </li> <li> <p>Furthermore, there is no evidence on quality of life due to a lack of data.</p> </li> </ul> </p> </section> <section id="CD007941-sec-0082"> <h3 class="title" id="CD007941-sec-0082">Overall completeness and applicability of evidence</h3> <p>All five identified eligible trials have been published, including more than 3000 patients. The trials included adults between 16 and 65 years of age (<a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>: 16 to 65 years; <a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a> and <a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>: 16 to 60 years; <a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>: up to 60 years of age; <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a>: older than 16 years of age) with unfavourable or advanced stage of HL. They provided sufficient evidence with regard to survival outcomes and adverse events but data on long‐term toxicity (e.g. infertility, pulmonary and cardiac toxicity) are still insufficient. </p> <p>Three trials (<a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a>, <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a> and <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a>) had follow‐ups of more than five years. However, long‐term data from <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a> could not be included in the meta‐analyses as the time‐to‐event outcomes have not been reported as hazard ratios (HRs) for each arm and authors did not provide detailed data. Moreover, long‐term secondary malignancies could only be evaluated from <a href="./references#CD007941-bbs2-0005" title="FedericoM , LuminariS , IannittoE , PolimenoG , MarcheselliL , MontaniniA , et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology2009;27:805‐11. FedericoM , MailanderV , Dell'OlioM , MerliF , BrugiatelliM , StelitanoC , et al. ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the initial treatment of patients with advanced Hodgkin Lymphoma (HL). Preliminary results of HD2000 GISL trial. Haematologica. 2007; Vol. 92:34. GobbiPG , RostiV , ValentinoF , BonettiE , MerliF , StelitanoC , et al. The early‐ and intermediate‐term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. Clinical Lymphoma &amp; Myeloma2009;9:425‐9. GobbiPG , ValentinoF , DanovaM , MorabitoF , RovatiB , MammiC , et al. Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports2009;21:1029‐35. Gruppo Italiano Studio Linfomi. Treatment of Advanced Hodgkin's Disease (Stages IIB‐III‐IV) (HD2000), ( NCT00443677). http://www.clinicaltrial.gov/ct2/show/NCT004436772007. MerliF , LuminariS , GobbiP G , CascavillaN , MammiC , IlariucciF , et al. Long‐term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP‐EBV‐CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. Journal of Clinical Oncology2016;34(11):1175‐81. MorabitoF , HohausS , MammiC , MarcheselliL , GentileM , MerliF , et al. Role of glutathione‐S‐transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. Leukemia &amp; Lymphoma2012;53(3):406‐10. ">HD 2000</a> as the analysis did not adhere to intention‐to‐treat analysis. </p> <p>Unfortunately, quality of life was not reported, although evaluated in one trial.</p> </section> <section id="CD007941-sec-0083"> <h3 class="title" id="CD007941-sec-0083">Quality of the evidence</h3> <p>The overall risk of performance and detection bias was low for OS, but was high for other outcomes, as therapy blinding was not feasible. The remaining 'Risk of bias' domains were low and unclear. </p> <p>The quality of evidence is high for OS, with enough events and precise results allowing meaningful statements. The quality of evidence is moderate for PFS, as the open‐label design of the included trials could lead to performance or detection biases. We downgraded by one level for this outcome. The quality of evidence is low for adverse events, due to the small number of events leading to highly imprecise results (downgraded by two points). The quality of evidence for treatment‐related mortality and secondary AML or MDS is judged at low, due to a very small number of events leading to very high imprecision (downgraded by two points). The quality of evidence for secondary malignancies is low, downgraded by one point due to small number of events leading to imprecision and downgraded by one point due to indirect results because of the short follow‐up period. To detect meaningful differences in terms of secondary malignancies, the follow‐up period should be at least 15 years. </p> <p>The quality of evidence is very low quality for infertility, due to high imprecision, resulting in downgrading by two points. We downgraded one point for indirectness as secondary amenorrhoea was measured instead of infertility. Moreover, no trial reported results for male fertility. </p> <p>We did not identify risk of publication bias, as all registered trials are published and we are not aware of further ongoing studies or completed studies that have not been published. </p> </section> <section id="CD007941-sec-0084"> <h3 class="title" id="CD007941-sec-0084">Potential biases in the review process</h3> <p>To prevent bias within the review, only randomised controlled trials (RCTs) were considered. In addition, all important conference proceedings were searched up to their latest issues. We tried to avoid bias by performing all relevant processes in duplicate. We are not aware of any obvious deficiencies in our review process. However, the small number of trials included in this analysis could lead to publication bias, as we could not generate a funnel plot. However, as mentioned before, we did not identify risk of publication bias, as all registered trials are published and we are not aware of further ongoing studies or completed studies that have not been published. </p> <p>One concern associated with the <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a> trial was that randomisation to the escalated BEACOPP arm started later than the randomisation to the other two arms. Furthermore, randomisation to the COPP/ABVD arm was stopped after the first interim analysis due to the fact that both BEACOPP groups together were statistically significantly superior to COPP/ABVD in terms of the rate of freedom from treatment failure (<a href="./references#CD007941-bbs2-0053" title="DiehlV , SteinH , HummelM , ZollingerR , ConnorsJM . Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology: American Society of Hematology Education Program2003, issue 1520‐4391:225‐47. ">Diehl 2003</a>). According to this potential risk of bias, the analyses of OS and PFS were based on data of patients recruited within the same time period (COOPP/ABVD N = 177, BEACOPP N = 265). </p> <p>In summary, there is maximum likelihood that all relevant studies were identified, all relevant data could be obtained and the review process (searching, data collection, analysis) did not introduce bias into the review. </p> </section> <section id="CD007941-sec-0085"> <h3 class="title" id="CD007941-sec-0085">Agreements and disagreements with other studies or reviews</h3> <p>Within this context two trials (<a href="./references#CD007941-bbs2-0056" title="EichH T , DiehlV , GorgenH , PabstT , MarkovaJ , DebusJ , et al. Intensified chemotherapy and dose‐reduced involved‐field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial. Journal of Clinical Oncology2010;28:4199‐206. ">Eich 2010</a>; <a href="./references#CD007941-bbs2-0060" title="FermeC , EghbaliH , MeerwaldtJ H , RieuxC , BosqJ , BergerF , et al. Chemotherapy plus involved‐field radiation in early‐stage Hodgkin's disease. New England Journal of Medicine2007;357:1916‐27. ">Ferme 2007a</a>), examined the treatment with four to six cycles ABVD compared to four cycles BEACOPP baseline. Neither showed an advantage of BEACOPP baseline regarding response, freedom from treatment failure/event‐free survival, nor OS. However, following the rationale to aim at improved outcomes by dose escalation, the HD14 trial was designed to examine the even more intensive regimen of two cycles of escalated BEACOPP, plus two cycles of ABVD compared to four cycles of ABVD, both followed by 30 Gray involved field radiotherapy (IF‐RT) for early unfavourable HL. This further intensification might be a success, because after a median follow‐up of 3.5 years the trial showed an improved freedom from treatment failure for patients who received escalated BEACOPP (HR 0.49, 95% CI 0.34 to 0.71), even if a difference with regard to OS was not detectible within this short period (<a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a>). </p> <p>The discussion on pros and cons of escalated BEACOPP compared to other treatment options, especially ABVD, for HL patients with advanced‐stage disease is active since the <a href="./references#CD007941-bbs2-0003" title="Erratum: Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease (New England Journal of Medicine (June 12, 2003) 348 (2386‐2395)). New England Journal of Medicine2005; Vol. 353, issue 7:744. BehringerK , BreuerK , ReinekeT , MayM , NogovaL , KlimmB , et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2005;23(30):7555‐64. DiehlV , BrillantC , FranklinJ , EngertA , PfistnerB , GreilR , et al. Optimisation of BEACOPP for advanced Hodgkin's disease: Further results from German Hodgkin Study Group trials HD9 and HD12. Annals of Oncology. 2005; Vol. 16 Suppl 5, issue 12:51. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood. 2004; Vol. 104, issue 11 Part 1:91‐2. DiehlV , BrillantC , FranklinJ , HermannR , GreilR , EngertA , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9‐ and HD12‐ trials of the German Hodgkin Study Group (GHSG). Blood2004;104(11):307. DiehlV , EngertA , BrillantC , FranklinJ , PfistnerB , HerrmannR , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: Latest results from the German Hodgkin Study Group trials for treatment optimisation. Haematologica. 2005; Vol. 90, issue Suppl 2:141‐2. DiehlV , FranklinJ , HasencleverD , TeschH , PfreundschuhM , LathanB , et al. BEACOPP, a new dose‐escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced‐stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology1998;16(12):3810‐21. DiehlV , FranklinJ , PaulusU , EngertA , HasencleverD , WolfJ , et al. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Annals of Oncology. 2002; Vol. 13, issue Suppl 2:25. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. BEACOPP chemotherapy with dose escalation in advanced Hodgkin's disease: Final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood. 2001; Vol. 98, issue 11 Pt 1:769a. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , HasencleverD , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease: final results of the randomized trial HD9 of the German Hodgkin Lymphoma Study Group. Hematology Journal. 2002; Vol. 3, issue Suppl 1:254. DiehlV , FranklinJ , PaulusU , EngertA , WolfJ , LoefflerM . BEACOPP chemotherapy improves survival, and dose escalation further improves tumour control in advanced stage Hodgkin's disease: GHSG HD9 results. Leukemia &amp; Lymphoma. 2001; Vol. 42, issue Suppl 2:16‐7. DiehlV , FranklinJ , PfistnerB , EngertA . 10‐Year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma. Haematologica. 2007; Vol. 92, issue Suppl 5:69‐70. DiehlV , FranklinJ , PfistnerB , EngertA . Ten‐year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). Journal of Clinical Oncology. 2007; Vol. 25, issue 18S Part I:444. DiehlV , FranklinJ , PfreundschuhM , LathanB , PaulusU , HasencleverD , et al. Standard and increased‐dose BEACOPP chemotherapy compared with COPP‐ABVD for advanced Hodgkin's disease.[see comment][erratum appears in N Engl J Med. 2005 Aug 18;353(7):744 Note: dosage error in text]. New England Journal of Medicine2003;348(24):2386‐95. DiehlV , FranklinJ , SieberM , HasencleverD , WolfJ , EngertA . Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's disease: updated results of the German Hodgkin's Lymphoma Study Group. Blood. 2000; Vol. 96, issue 11:576a. DiehlV , FranklinJ , TeschH , LoefflerM , HasencleverD , PfreundschuhM , et al. Dose escalation of BEACOPP chemotherapy for advanced Hodgkin's disease in the HD9 trial of the German Hodgkin's Lymphoma Study Group (GHSG). Journal of Clinical Oncology. 2000; Vol. 19:4a. DiehlV , FranklinJG , PfistnerB , PaulusU , WolfJ , EngertA . Standart and increased dose BEACOPP chemotherapy for advanced Hodgkin's disease: longer follow‐up of the HD9 trial of the German Hodgkin's lymphoma Study Group. European Journal of Haematology. 2004; Vol. 73, issue Suppl 65:46‐7. DiehlV , JostingA . Hodgkin's disease. Cancer Journal2000;6(Suppl 2):S150‐8. DiehlV , LathanB , EngertA , RuefferU , SieberM , WolfJ , et al. Interim analysis of the HD9 study of the German Hodgkin Study Group ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Blood. 1997; Vol. 90, issue 10 Suppl 1:339a. DiehlV , SieberM , FranklinJ , RufferU , TeschH , HasencleverD , et al. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's disease: promising results of the fourth interim analysis of the HD9 trial. Annals of Oncology. 1999; Vol. 10, issue Suppl 3:22. DiehlV , TeschH , FranklinJ , HasencleverD , RufferU , SieberM , et al. BEACOPP chemotherapy for advanced Hodgkin's disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation. Blood. 1999; Vol. 94, issue 10 Suppl 1:527a. DiehlV , WolfJ , FranklinJ , EngertA , HasencleverD , Muller‐HermelinkH , et al. BEACOPP chemotherapy for advanced Hodgkin's disease (HD) is more effective with dose escalation: German Hodgkin Lymphoma Study Group interim results. Annals of Oncology. 2000; Vol. 11, issue Suppl 4:99‐100. EkertH . Chemotherapy for Hodgkin's disease.[comment]. New England Journal of Medicine2003;349(12):1186‐7. EngertA , BallovaV , HaverkampH , PfistnerB , JostingA , DuhmkeE , et al. Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology2005;23(22):5052‐60. EngertA , DiehlV , FranklinJ , LohriA , DorkenB , LudwigW D , et al. Escalated‐dose BEACOPP in the treatment of patients with advanced‐stage Hodgkin's lymphoma: 10 years of follow‐up of the GHSG HD9 study. Journal of Clinical Oncology2009;27:4548‐54. EngertA , FranklinJ , DiehlV . Long‐term follow‐up of BEACOPP escalated chemotherapy in patients with advanced‐stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood. 2007; Vol. 110, issue 11. JostingA , WiedenmannS , FranklinJ , MayM , SieberM , WolfJ , et al. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology2003;21(18):3440‐6. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . The role of chemotherapy dose intensity in the treatment of advanced‐ stage Hodgkin's disease. Klinicka Onkologie2000;13(2):52‐7. MarkovaJ , KocovaJ , MalinovaB , StriteskyJ , FeltlD , DiehlV . Treatment of Hodgkin's disease according to the protocols of the German Hodgkin's disease study group. Our experience and results. Vnitrni Lekarstvi2000;46(4):225‐31. MarkovaJ , MalinovaB , StriteskyJ , DiehlV . Treatment of advanced stage Hodgkin's disease according to a protocol from the German Hodgkin's Lymphoma Study Group (GHSG), our experience and results. Klinicka Onkologie1998;11(2):50‐4. SieniawskiM , ReinekeT , JostingA , NogovaL , BehringerK , HalbsguthT , et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Annals of Oncology2008;19(10):1795‐801. TeschH , DiehlV , LathanB , EngertA , FranklinJ , RuefferU , et al. Interim analysis of the HD9 study of the German Hodgkin group (GHSG) ‐ BEACOPP is more effective than COPP‐ABVD in advanced stage Hodgkin's disease. Leukemia and Lymphoma. 1998; Vol. 29, issue Suppl 1. WolfJ , FranklinJ , DiehlV . Primary therapy of Hodgkin's disease: New strategies for use of chemotherapy. Onkologie2000;6(12):1169‐77. ">GHSG HD9</a> trial has been published. All included trials in this review that examined patients with newly diagnosed unfavourable or advanced stage HL showed an improved PFS with BEACOPP escalated compared to ABVD. With the inclusion of the recently completed trial <a href="./references#CD007941-bbs2-0001" title="CardeP , KarrashM , FortpiedC , BriceP , KhaledH , CasasnovasO , et al. Eight cycles of ABVD versus four cycles of BEACOPP escalated plus four cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, high‐risk Hodgkin lymphoma: First results of the Phase III EORTC 20012 Intergroup Trial. Journal of Clinical OncologyJune 2016;34(17):2028‐36. CardePP , KarraschM , FortpiedC , BriceP , KhaledHM , CaillotD , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles =&gt; 4 baseline) in stage III‐IV high‐risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Journal of Clinical Oncology, 30, (suppl; Abstract 8002). 2012. CardePP , LinchDC , DivineM , SuredaA , MeyerRM , MaD , et al. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin's Lymphoma, (NCT00049595). http://clinicaltrials.gov/ct2/show/NCT000495952010. MounierN , BriceP , BolognaS , BriereJ , GaillardI , HeczkoM , et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low‐risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Annals of OncologyMay 2014, issue 25:1622‐8. ">EORTC 20012</a> in the meta‐analysis, this increased PFS is now also translated in an overall survival advantage with BEACOPP escalated. This result is in line with a comprehensive network meta‐analysis in advanced stage HL patients, favouring BEACOPP escalated over ABVD (<a href="./references#CD007941-bbs2-0077" title="SkoetzN , TrelleS , RanceaM , HaverkampH , DiehlV , EngertA , et al. Effect of initial treatment strategy on survival of patients with advanced‐stage Hodgkin's lymphoma: a systematic review and network meta‐analysis. Lancet Oncology2013;14(10):943‐52. [PUBMED: 23948348] ">Skoetz 2013</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007941-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007941-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/full#CD007941-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007941-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/full#CD007941-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Analysis of Overall Survival, outcome: 1.1 OS ‐ all ‐ same recruitment period between the 2 arms (HD9)." data-id="CD007941-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Analysis of Overall Survival, outcome: 1.1 OS ‐ all ‐ same recruitment period between the 2 arms (HD9). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/full#CD007941-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Analysis of Progression Free Survival, outcome: 2.1 PFS ‐ all ‐ same recruitment period between the 2 arms (HD9)." data-id="CD007941-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Analysis of Progression Free Survival, outcome: 2.1 PFS ‐ all ‐ same recruitment period between the 2 arms (HD9). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/full#CD007941-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Analysis overall survival, Outcome 1 OS ‐ all ‐ same recruitment period between the 2 arms (HD9)." data-id="CD007941-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Analysis overall survival, Outcome 1 OS ‐ all ‐ same recruitment period between the 2 arms (HD9). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Analysis overall survival, Outcome 2 OS subgrouped by stage of disease." data-id="CD007941-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Analysis overall survival, Outcome 2 OS subgrouped by stage of disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Analysis overall survival, Outcome 3 OS subgrouped by treatment." data-id="CD007941-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Analysis overall survival, Outcome 3 OS subgrouped by treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Analysis overall survival, Outcome 4 OS subgrouped by number of cycles of escalated BEACOPP." data-id="CD007941-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Analysis overall survival, Outcome 4 OS subgrouped by number of cycles of escalated BEACOPP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Analysis overall survival, Outcome 5 OS subgrouped by length of follow‐up." data-id="CD007941-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Analysis overall survival, Outcome 5 OS subgrouped by length of follow‐up.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Analysis overall survival, Outcome 6 OS subgrouped by radiotherapy." data-id="CD007941-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Analysis overall survival, Outcome 6 OS subgrouped by radiotherapy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Analysis overall survival, Outcome 7 OS ‐ all recruited patients (HD9) with potential risk of bias due to different time periods of recruitment." data-id="CD007941-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Analysis overall survival, Outcome 7 OS ‐ all recruited patients (HD9) with potential risk of bias due to different time periods of recruitment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Analysis of progression‐free survival (PFS), Outcome 1 PFS ‐ all ‐ same recruitment period between the 2 arms (HD9)." data-id="CD007941-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Analysis of progression‐free survival (PFS), Outcome 1 PFS ‐ all ‐ same recruitment period between the 2 arms (HD9). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Analysis of progression‐free survival (PFS), Outcome 2 PFS subgrouped by stage of disease." data-id="CD007941-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Analysis of progression‐free survival (PFS), Outcome 2 PFS subgrouped by stage of disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Analysis of progression‐free survival (PFS), Outcome 3 PFS subgrouped by treatment." data-id="CD007941-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Analysis of progression‐free survival (PFS), Outcome 3 PFS subgrouped by treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Analysis of progression‐free survival (PFS), Outcome 4 PFS subgrouped by number of cycles of escalated BEACOPP." data-id="CD007941-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Analysis of progression‐free survival (PFS), Outcome 4 PFS subgrouped by number of cycles of escalated BEACOPP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Analysis of progression‐free survival (PFS), Outcome 5 PFS subgrouped by length of follow‐up." data-id="CD007941-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Analysis of progression‐free survival (PFS), Outcome 5 PFS subgrouped by length of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Analysis of progression‐free survival (PFS), Outcome 6 PFS subgrouped by type of radiotherapy." data-id="CD007941-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Analysis of progression‐free survival (PFS), Outcome 6 PFS subgrouped by type of radiotherapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Analysis of progression‐free survival (PFS), Outcome 7 PFS ‐ all recruited patients (HD9) with potential risk of bias due to different time periods of recruitment." data-id="CD007941-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Analysis of progression‐free survival (PFS), Outcome 7 PFS ‐ all recruited patients (HD9) with potential risk of bias due to different time periods of recruitment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Analysis of treatment‐related mortality, Outcome 1 Treatment‐related mortality." data-id="CD007941-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Analysis of treatment‐related mortality, Outcome 1 Treatment‐related mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Analysis of treatment‐related mortality, Outcome 2 TRM subgrouped by stage of disease." data-id="CD007941-fig-0020" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Analysis of treatment‐related mortality, Outcome 2 TRM subgrouped by stage of disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Analysis of treatment‐related mortality, Outcome 3 TRM subgrouped by number of cycles of escalated BEACOPP." data-id="CD007941-fig-0021" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Analysis of treatment‐related mortality, Outcome 3 TRM subgrouped by number of cycles of escalated BEACOPP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Analysis of treatment‐related mortality, Outcome 4 TRM subgrouped by type of radiotherapy." data-id="CD007941-fig-0022" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Analysis of treatment‐related mortality, Outcome 4 TRM subgrouped by type of radiotherapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Analysis of secondary malignancies, Outcome 1 Secondary malignancies." data-id="CD007941-fig-0023" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Analysis of secondary malignancies, Outcome 1 Secondary malignancies.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Analysis of secondary malignancies, Outcome 2 SM subgrouped by stage of disease." data-id="CD007941-fig-0024" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Analysis of secondary malignancies, Outcome 2 SM subgrouped by stage of disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Analysis of secondary malignancies, Outcome 3 SM subgrouped by treatment." data-id="CD007941-fig-0025" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Analysis of secondary malignancies, Outcome 3 SM subgrouped by treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Analysis of secondary malignancies, Outcome 4 SM subgrouped by number of cycles of escalated BEACOPP." data-id="CD007941-fig-0026" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Analysis of secondary malignancies, Outcome 4 SM subgrouped by number of cycles of escalated BEACOPP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Analysis of secondary malignancies, Outcome 5 SM subgrouped by type of radiotherapy." data-id="CD007941-fig-0027" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Analysis of secondary malignancies, Outcome 5 SM subgrouped by type of radiotherapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Analysis of secondary malignancies, Outcome 6 SM subgrouped by length of follow‐up." data-id="CD007941-fig-0028" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Analysis of secondary malignancies, Outcome 6 SM subgrouped by length of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Analysis of AML or MDS, Outcome 1 AML or MDS." data-id="CD007941-fig-0029" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Analysis of AML or MDS, Outcome 1 AML or MDS.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Analysis of AML or MDS, Outcome 2 AML/MDS subgrouped by stage of disease." data-id="CD007941-fig-0030" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Analysis of AML or MDS, Outcome 2 AML/MDS subgrouped by stage of disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Analysis of AML or MDS, Outcome 3 AML/MDS subgrouped by treatment." data-id="CD007941-fig-0031" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Analysis of AML or MDS, Outcome 3 AML/MDS subgrouped by treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Analysis of AML or MDS, Outcome 4 AML/MDS subgrouped by number of cycles of escalated BEACOPP." data-id="CD007941-fig-0032" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Analysis of AML or MDS, Outcome 4 AML/MDS subgrouped by number of cycles of escalated BEACOPP. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Analysis of AML or MDS, Outcome 5 AML/MDS subgrouped by type of radiotherapy." data-id="CD007941-fig-0033" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Analysis of AML or MDS, Outcome 5 AML/MDS subgrouped by type of radiotherapy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Analysis of AML or MDS, Outcome 6 AML/MDS subgrouped by length of follow‐up." data-id="CD007941-fig-0034" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Analysis of AML or MDS, Outcome 6 AML/MDS subgrouped by length of follow‐up.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Analysis of fertility, Outcome 1 Secondary amenorrhoea." data-id="CD007941-fig-0035" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Analysis of fertility, Outcome 1 Secondary amenorrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Analysis of anaemia, Outcome 1 Anaemia." data-id="CD007941-fig-0036" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Analysis of anaemia, Outcome 1 Anaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Analysis of infection, Outcome 1 Infection." data-id="CD007941-fig-0037" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Analysis of infection, Outcome 1 Infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Analysis of neutropenia, Outcome 1 Neutropenia." data-id="CD007941-fig-0038" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Analysis of neutropenia, Outcome 1 Neutropenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Analysis of thrombocytopenia, Outcome 1 Thrombocytopenia." data-id="CD007941-fig-0039" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Analysis of thrombocytopenia, Outcome 1 Thrombocytopenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Analysis of alopecia, Outcome 1 Alopecia." data-id="CD007941-fig-0040" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Analysis of alopecia, Outcome 1 Alopecia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Analysis of constipation, Outcome 1 Constipation." data-id="CD007941-fig-0041" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Analysis of constipation, Outcome 1 Constipation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Analysis of mucositis, Outcome 1 Mucositis." data-id="CD007941-fig-0042" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Analysis of mucositis, Outcome 1 Mucositis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Analysis of nausea/vomiting, Outcome 1 Nausea/vomiting." data-id="CD007941-fig-0043" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 Analysis of nausea/vomiting, Outcome 1 Nausea/vomiting.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Analysis of neurologic toxicity, Outcome 1 Neurologic." data-id="CD007941-fig-0044" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 Analysis of neurologic toxicity, Outcome 1 Neurologic.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-016-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-016-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Analysis of pain, Outcome 1 Pain." data-id="CD007941-fig-0045" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-016-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 Analysis of pain, Outcome 1 Pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-016-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-017-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-017-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Analysis of respiratory, Outcome 1 Respiratory." data-id="CD007941-fig-0046" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-017-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 Analysis of respiratory, Outcome 1 Respiratory.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-017-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-018-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-018-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Analysis of skin, Outcome 1 Skin." data-id="CD007941-fig-0047" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-018-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18 Analysis of skin, Outcome 1 Skin.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-018-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-019-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-019-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Analysis of heart disease, Outcome 1 heart." data-id="CD007941-fig-0048" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-019-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19 Analysis of heart disease, Outcome 1 heart.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-019-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-020-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-020-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Analysis of freedom from first progression, Outcome 1 Freedom from first progression." data-id="CD007941-fig-0049" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-020-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20 Analysis of freedom from first progression, Outcome 1 Freedom from first progression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-020-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007941-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/urn:x-wiley:14651858:media:CD007941:CD007941-CMP-021-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_t/tCD007941-CMP-021-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Analysis of complete response (CR) rate, Outcome 1 CR." data-id="CD007941-fig-0050" src="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-021-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21 Analysis of complete response (CR) rate, Outcome 1 CR.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/media/CDSR/CD007941/image_n/nCD007941-CMP-021-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007941-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Escalated BEACOPP versus chemotherapy including ABVD</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Patients with early unfavourable or advanced stage HL<br/> <b>Setting:</b> Hospitals<br/> <b>Intervention:</b> BEACOPP<br/> <b>Comparison:</b> ABVD </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ABVD</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with BEACOPP</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality<br/> follow up: median 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.74<br/> (0.57 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3142<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>To provide correct results by using the GRADE software, we calculated mortality instead of overall survival </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000<br/> (70 to 117) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression, relapse or death<br/> follow up: median 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.54<br/> (0.45 to 0.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3142<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>To provide correct results by using the GRADE software, we calculated progression, relapse or death instead of progression‐free survival </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000<br/> (121 to 168) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse event: treatment‐related mortality</p> <p>follow up median 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.15<br/> (0.93 to 4.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2700<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/> (5 to 25) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse event: secondary malignancies</p> <p>follow up median 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.00<br/> (0.68 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3332<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5, 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/> (20 to 42) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse event: secondary malignancies: AML or MDS</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.90<br/> (1.36 to 11.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3332<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (3 to 29) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse event: infertility (secondary amenorrhoea)</p> <p>follow up median 5 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.37<br/> (0.83 to 2.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>106<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>4, 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In the text referred to as infertility.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>375 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>514 per 1000<br/> (311 to 847) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Quality of life</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> we estimated the risk of mortality after 5 years in the ABVD arm as being 12% </p> <p><sup>2</sup> we estimated the risk of progress, relapse or mortality after 5 years in the ABVD arm as being 25% </p> <p><sup>3</sup> one level down due to the open‐label design of the included trials which could lead to performance or detection biases </p> <p><sup>4</sup> two levels down due to very few events and wide confidence intervals (imprecision) </p> <p><sup>5</sup> one level down due to few events and wide confidence intervals (imprecision) </p> <p><sup>6</sup> one level down due to indirect results (follow‐up period not long enough to detect meaningful differences) </p> <p><sup>7</sup> one level down due to indirect results (secondary amenorrhoea measured instead of infertility) (indirectness) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Escalated BEACOPP versus chemotherapy including ABVD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/full#CD007941-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007941-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">The escalated BEACOPP regimen</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single Dose (mg/m<sup>2</sup>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Route</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Days given*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleomycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Etoposide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doxorubicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclophosphamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vincristine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Procarbazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P.O.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P.O.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>G‐CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>from day 8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>*the regimen was repeated on day 22</p> <p>IV: intravenously, P.O.: orally, SC: subcutaneous</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">The escalated BEACOPP regimen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/full#CD007941-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007941-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events (reported by two trials)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Name of trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Experimental arm (N)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Control arm (N)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007941-bbs2-0002" title="BehringerK , MuellerH , GoergenH , ThielenI , EiblAD , StumpfV , et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of Clinical Oncology2013;31(2):231‐9. BehringerK , ThielenI , MuellerH , GoergenH , EiblAD , RosenbrockJ , et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Annals of Oncology2012;23(7):1818‐25. BorchmannP , EngertA , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IFRT in patients with early unfavourable Hodgkin Lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood. 2008; Vol. 112:367. EngertA , BorchmannP , PluetschowA , FuchsM , MarkovaJ , LohriA , et al. Dose‐intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by cycles of ABVD and involved field radiotherapy (IF‐RT) is superior to 4 cycles of ABVD and IF‐RT in patients with early unfavourable Hodgkin lymphoma (HL): An analysis of the German Hodgkin Study Group (GHSG). Haematologica. 2009. EngertA , BorchmannP , PluetschowA , VonTresckowB , MarkovaJ , HitzF , et al. Dose‐escalation with BEACOPP escalated is superior to ABVD in the combined‐modality treatment of early unfavourable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood. 2010. vonTresckowB , PlutschowA , FuchsM , KlimmB , MarkovaJ , LohriA , et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. Journal of Clinical Oncology2012;30:907‐13. ">GHSG HD14</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal, others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43/744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/757</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urogenital tract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/757</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drug fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/757</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allergy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/757</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007941-bbs2-0004" title="FondazioneMichelangelo . Study Comparing Doxorubicin, Bleomycin,Vinblastine, Dacarbazine (ABVD) vs Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone (BEACOPP), ( NCT01251107). http://www.clinicaltrial.gov/ct2/show/NCT012511072010. GianniAM , RambaldiA , ZinzaniP , LevisA , BrusamolinoE , PulsoniA , et al. Comparable 3‐year outcome following ABVD or BEACOPP first‐line chemotherapy, plus pre‐planned high‐dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract no. 8506]. Journal of Clinical Oncology. 2008; Vol. 26, issue 15S part I:455. VivianiS , ZinzaniPL , RambaldiA , BrusamolinoE , LevisA , BonfanteV , et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high‐dose salvage is planned. New England Journal of Medicine2011;365(3):203‐12. ">GSM‐HD 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal, others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fever of unknown reason</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/166</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events (reported by two trials)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/full#CD007941-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Analysis overall survival</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 OS ‐ all ‐ same recruitment period between the 2 arms (HD9) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.57, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 OS subgrouped by stage of disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.57, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 early unfavourable stage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.54, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 advanced stage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.52, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 OS subgrouped by treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.57, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 only ABVD regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.60, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 ABVD including regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.40, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 OS subgrouped by number of cycles of escalated BEACOPP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.57, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 eight cycles of escalated BEACOPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.40, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 four cycles of escalated BEACOPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.52, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 two cycles of escalated BEACOPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.54, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 OS subgrouped by length of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.57, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 short‐term follow‐up (median length up to 5 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.60, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 long‐term follow‐up (median length 10 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.40, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 OS subgrouped by radiotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.57, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 without radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.42, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 with radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.56, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 OS ‐ all recruited patients (HD9) with potential risk of bias due to different time periods of recruitment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.52, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Analysis overall survival</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Analysis of progression‐free survival (PFS)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 PFS ‐ all ‐ same recruitment period between the 2 arms (HD9) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.45, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 PFS subgrouped by stage of disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.45, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 early unfavourable stage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.31, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 advanced stage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.46, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 PFS subgrouped by treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.45, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 only ABVD regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.45, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 ABVD including regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.34, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 PFS subgrouped by number of cycles of escalated BEACOPP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.45, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 eight cycles of escalated BEACOPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.34, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 four cycles of escalated BEACOPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.46, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 two cycles of escalated BEACOPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.31, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 PFS subgrouped by length of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.45, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 short‐term follow‐up (median length up to 5 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.45, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 long‐term follow‐up (median length 10 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.34, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 PFS subgrouped by type of radiotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.45, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 without radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.39, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 with radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.44, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 PFS ‐ all recruited patients (HD9) with potential risk of bias due to different time periods of recruitment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.43, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Analysis of progression‐free survival (PFS)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Analysis of treatment‐related mortality</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Treatment‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [0.93, 4.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 TRM subgrouped by stage of disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [0.93, 4.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 early unfavourable stage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.15 [0.49, 169.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 advanced stage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.69, 4.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 TRM subgrouped by number of cycles of escalated BEACOPP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [0.93, 4.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 four cycles of escalated BEAOPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.69, 4.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 two cycles of escalated BEACOPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.15 [0.49, 169.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 TRM subgrouped by type of radiotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [0.93, 4.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 without radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.26, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 with radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.13 [1.38, 27.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Analysis of treatment‐related mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Analysis of secondary malignancies</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Secondary malignancies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.68, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 SM subgrouped by stage of disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.68, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 early unfavourable stage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.45, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 advanced stage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.66, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 SM subgrouped by treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.68, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 only ABVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.59, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 ABVD including regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.57, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 SM subgrouped by number of cycles of escalated BEACOPP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.68, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 eight cycles of escalated BEACOPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.57, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 four cycles of escalated BEAOPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.52, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 two cycles of escalated BEACOPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.45, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 SM subgrouped by type of radiotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.68, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 without radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.50, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 with radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2783</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.62, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 SM subgrouped by length of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.68, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 short‐term follow‐up (median length up to 5 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.59, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 long‐term follow‐up (median length 10 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.57, 1.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Analysis of secondary malignancies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Analysis of AML or MDS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 AML or MDS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.90 [1.36, 11.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 AML/MDS subgrouped by stage of disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.90 [1.36, 11.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 early unfavourable stage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.01 [0.24, 104.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 advanced stage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.77 [1.22, 11.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 AML/MDS subgrouped by treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.90 [1.36, 11.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 only ABVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [0.71, 8.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 ABVD including regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.84 [1.04, 59.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 AML/MDS subgrouped by number of cycles of escalated BEACOPP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.90 [1.36, 11.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 eight cycles of escalated BEACOPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.84 [1.04, 59.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 four cycles of escalated BEAOPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [0.51, 8.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 two cycles of escalated BEACOPP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.01 [0.24, 104.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 AML/MDS subgrouped by type of radiotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.90 [1.36, 11.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 without radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.37, 10.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 with radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2783</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.27 [1.34, 20.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 AML/MDS subgrouped by length of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.90 [1.36, 11.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 short‐ term follow‐up (median length up to 5 years) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [0.71, 8.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 long‐ term follow‐up (median length 10 years) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.84 [1.04, 59.29]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Analysis of AML or MDS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Analysis of fertility</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Secondary amenorrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.83, 2.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Analysis of fertility</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Analysis of anaemia</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.67 [7.14, 15.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Analysis of anaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Analysis of infection</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.73 [2.58, 5.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Analysis of infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Analysis of neutropenia</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.52, 2.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Analysis of neutropenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Analysis of thrombocytopenia</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.12 [11.77, 27.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Analysis of thrombocytopenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Analysis of alopecia</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Alopecia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.78, 2.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Analysis of alopecia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Analysis of constipation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Constipation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>923</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.56, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Analysis of constipation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Analysis of mucositis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mucositis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.04 [3.72, 17.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Analysis of mucositis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Analysis of nausea/vomiting</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Nausea/vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.68, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Analysis of nausea/vomiting</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Analysis of neurologic toxicity</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Neurologic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [1.19, 3.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Analysis of neurologic toxicity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Analysis of pain</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.62 [1.76, 3.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Analysis of pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Analysis of respiratory</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Respiratory <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.01, 3.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Analysis of respiratory</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Analysis of skin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Skin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.45, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Analysis of skin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Analysis of heart disease</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 heart <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.21, 5.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Analysis of heart disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Analysis of freedom from first progression</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Freedom from first progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.27, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Analysis of freedom from first progression</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007941-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Analysis of complete response (CR) rate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 CR <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [1.01, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Analysis of complete response (CR) rate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007941.pub3/references#CD007941-tbl-0024">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007941.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007941-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007941-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007941-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD007941-note-0003">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD007941-note-0002">한국어</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007941-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007941\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007941\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007941\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007941\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007941\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007941\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007941\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007941\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007941\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007941\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007941\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007941\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007941\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007941\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007941\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007941\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007941\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007941\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007941.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007941.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007941.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007941.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007941.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725364173"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007941.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725364177"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007941.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e796e1c76936e',t:'MTc0MDcyNTM2NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 